

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAKLK1614

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 06	CAS REGISTRY enhanced with new experimental property tags
NEWS	3	AUG 06	FSTA enhanced with new thesaurus edition
NEWS	4	AUG 13	CA/CAPplus enhanced with additional kind codes for granted patents
NEWS	5	AUG 20	CA/CAPplus enhanced with CAS indexing in pre-1907 records
NEWS	6	AUG 27	Full-text patent databases enhanced with predefined patent family display formats from INPADOCDB
NEWS	7	AUG 27	USPATOLD now available on STN
NEWS	8	AUG 28	CAS REGISTRY enhanced with additional experimental spectral property data
NEWS	9	SEP 07	STN AnaVist, Version 2.0, now available with Derwent World Patents Index
NEWS	10	SEP 13	FORIS renamed to SOFIS
NEWS	11	SEP 13	INPADOCDB enhanced with monthly SDI frequency
NEWS	12	SEP 17	CA/CAPplus enhanced with printed CA page images from 1967-1998
NEWS	13	SEP 17	CAPplus coverage extended to include traditional medicine patents
NEWS	14	SEP 24	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	15	OCT 02	CA/CAPplus enhanced with pre-1907 records from Chemisches Zentralblatt
NEWS	16	OCT 19	BEILSTEIN updated with new compounds
NEWS	17	NOV 15	Derwent Indian patent publication number format enhanced
NEWS	18	NOV 19	WPIX enhanced with XML display format
NEWS	19	NOV 30	ICSD reloaded with enhancements
NEWS	20	DEC 04	LINPADOCDB now available on STN
NEWS	21	DEC 14	BEILSTEIN pricing structure to change
NEWS	22	DEC 17	USPATOLD added to additional database clusters
NEWS	23	DEC 17	IMSDRUGCONF removed from database clusters and STN
NEWS	24	DEC 17	DGENE now includes more than 10 million sequences
NEWS	25	DEC 17	TOXCENTER enhanced with 2008 MeSH vocabulary in MEDLINE segment
NEWS	26	DEC 17	MEDLINE and LMEDLINE updated with 2008 MeSH vocabulary
NEWS	27	DEC 17	CA/CAPplus enhanced with new custom IPC display formats
NEWS	28	DEC 17	STN Viewer enhanced with full-text patent content from USPATOLD
NEWS	29	JAN 02	STN pricing information for 2008 now available
NEWS EXPRESS	19	SEPTEMBER 2007:	CURRENT WINDOWS VERSION IS V8.2, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 19 SEPTEMBER 2007.
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS LOGIN			Welcome Banner and News Items

NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 16:06:05 ON 15 JAN 2008

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'CAPLUS' ENTERED AT 16:06:12 ON 15 JAN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 15 Jan 2008 VOL 148 ISS 3

FILE LAST UPDATED: 14 Jan 2008 (20080114/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>

=> expand breda cullen

ENTER FIELD CODE (BI):au

E1	3	BREDA COIMBRA H/AU
E2	17	BREDA COLETTE/AU
E3	0 -->	BREDA CULLEN/AU
E4	4	BREDA D/AU
E5	3	BREDA DANIELA/AU
E6	1	BREDA DANIELI/AU
E7	7	BREDA E/AU
E8	2	BREDA EDUARDO/AU
E9	6	BREDA ELENA/AU
E10	3	BREDA ENRICO/AU
E11	4	BREDA ENZO/AU
E12	9	BREDA ERNEST J/AU

=> expand breda mary cullen

ENTER FIELD CODE (BI):au

E1	1	BREDA MARCOS SABEDOTTI/AU
E2	3	BREDA MARLI/AU
E3	0 -->	BREDA MARY CULLEN/AU
E4	1	BREDA MARZIA/AU
E5	8	BREDA MASSIMO/AU
E6	2	BREDA MERCIA/AU
E7	1	BREDA MICHAEL/AU
E8	4	BREDA MILOSLAV/AU
E9	1	BREDA MIROSLAV/AU
E10	3	BREDA MOURAO MARCELO/AU
E11	16	BREDA N/AU
E12	2	BREDA NATHALIE/AU

=> expand derek walker silcock

ENTER FIELD CODE (BI):au

E1	1	DEREK TEARE J/AU
E2	2	DEREK V/AU
E3	0 -->	DEREK WALKER SILCOCK/AU
E4	10	DEREK WOOLLINS J/AU
E5	1	DEREKA A N/AU
E6	5	DEREKA X E/AU
E7	13	DEREKAS A/AU
E8	1	DEREKAS ALIZ/AU
E9	1	DEREKAS BARNABAS/AU
E10	1	DEREKES G/AU
E11	40	DEREKH P A/AU
E12	3	DEREKH PETR A/AU

=> expand derek silcock

ENTER FIELD CODE (BI):au

E1	1	DEREK ROBERT MARSDEN/AU
E2	1	DEREK SIDNEY IZZARD/AU
E3	0 -->	DEREK SILCOCK/AU
E4	1	DEREK TADEUSZ/AU
E5	1	DEREK TEARE J/AU
E6	2	DEREK V/AU
E7	10	DEREK WOOLLINS J/AU
E8	1	DEREKA A N/AU
E9	5	DEREKA X E/AU
E10	13	DEREKAS A/AU
E11	1	DEREKAS ALIZ/AU
E12	1	DEREKAS BARNABAS/AU

=> expand silcock

ENTER FIELD CODE (BI):au

E1	3	SILCKERODT WERNER/AU
E2	1	SILCO JOHN/AU
E3	0 -->	SILCOCK/AU
E4	3	SILCOCK ALAN/AU
E5	1	SILCOCK ALAN J/AU
E6	1	SILCOCK CLAIRE L/AU
E7	5	SILCOCK D J/AU
E8	1	SILCOCK DEBORAH/AU
E9	2	SILCOCK DEBORAH J/AU
E10	11	SILCOCK DEREK/AU
E11	10	SILCOCK DEREK WALTER/AU
E12	3	SILCOCK E J/AU

=> search L7 and L10

L7 NOT FOUND

The L-number entered could not be found. To see the definition

of L-numbers, enter DISPLAY HISTORY at an arrow prompt (=>).

```
=> search e7 and e10 and e11
      5 "SILCOCK D J"/AU
      11 "SILCOCK DEREK"/AU
      10 "SILCOCK DEREK WALTER"/AU
L1      0 "SILCOCK D J"/AU AND "SILCOCK DEREK"/AU AND "SILCOCK DEREK WALTER"
      R"/AU
```

```
=> search e7 or e10 or e11
      5 "SILCOCK D J"/AU
      11 "SILCOCK DEREK"/AU
      10 "SILCOCK DEREK WALTER"/AU
L2      26 "SILCOCK D J"/AU OR "SILCOCK DEREK"/AU OR "SILCOCK DEREK WALTER"
      /AU
```

```
=> display l2
ENTER ANSWER NUMBER OR RANGE (1):1-12
ENTER DISPLAY FORMAT (BIB):d l2 ibib ab
'D' IS NOT A VALID FORMAT FOR FILE 'CAPLUS'
```

The following are valid formats:

```
ABS ----- GI and AB
ALL ----- BIB, AB, IND, RE
APPS ----- AI, PRAI
BIB ----- AN, plus Bibliographic Data and PI table (default)
CAN ----- List of CA abstract numbers without answer numbers
CBIB ----- AN, plus Compressed Bibliographic Data
CLASS ----- IPC, NCL, ECLA, FTERM
DALL ----- ALL, delimited (end of each field identified)
DMAX ----- MAX, delimited for post-processing
FAM ----- AN, PI and PRAI in table, plus Patent Family data
FBIB ----- AN, BIB, plus Patent FAM
IND ----- Indexing data
IPC ----- International Patent Classifications
MAX ----- ALL, plus Patent FAM, RE
PATS ----- PI, SO
SAM ----- CC, SX, TI, ST, IT
SCAN ----- CC, SX, TI, ST, IT (random display, no answer numbers;
      SCAN must be entered on the same line as the DISPLAY,
      e.g., D SCAN or DISPLAY SCAN)
STD ----- BIB, CLASS

IABS ----- ABS, indented with text labels
IALL ----- ALL, indented with text labels
IBIB ----- BIB, indented with text labels
IMAX ----- MAX, indented with text labels
ISTD ----- STD, indented with text labels

OBIB ----- AN, plus Bibliographic Data (original)
OIBIB ----- OBIB, indented with text labels

SBIB ----- BIB, no citations
SIBIB ----- IBIB, no citations

HIT ----- Fields containing hit terms
HITIND ----- IC, ICA, ICI, NCL, CC and index field (ST and IT)
      containing hit terms
HITRN ----- HIT RN and its text modification
HITSTR ----- HIT RN, its text modification, its CA index name, and
```

its structure diagram
HITSEQ ----- HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
FHITSTR ----- First HIT RN, its text modification, its CA index name, and
its structure diagram
FHITSEQ ----- First HIT RN, its text modification, its CA index name, its
structure diagram, plus NTE and SEQ fields
KWIC ----- Hit term plus 20 words on either side
OCC ----- Number of occurrence of hit term and field in which it occurs

To display a particular field or fields, enter the display field
codes. For a list of the display field codes, enter HELP DFIELDS at
an arrow prompt (=>). Examples of formats include: TI; TI,AU; BIB,ST;
TI,IND; TI,SO. You may specify the format fields in any order and the
information will be displayed in the same order as the format
specification.

All of the formats (except for SAM, SCAN, HIT, HITIND, HITRN, HITSTR,
FHITSTR, HITSEQ, FHITSEQ, KWIC, and OCC) may be used with DISPLAY ACC
to view a specified Accession Number.

ENTER DISPLAY FORMAT (BIB):ibib ab

L2 ANSWER 1 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2007:640559 CAPLUS
DOCUMENT NUMBER: 147:39279
TITLE: Wound dressings comprising oxidized cellulose and
human recombinant collagen
INVENTOR(S): Boyle, Clare; Silcock, Derek Walter; Cullen, Breda
Mary
PATENT ASSIGNEE(S): Ethicon, Inc., USA
SOURCE: Eur. Pat. Appl., 10pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1795210	A2	20070613	EP 2006-256271	20061208
EP 1795210	A3	20070905		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU				
GB 2433029	A	20070613	GB 2005-25130	20051209
CA 2568455	A1	20070609	CA 2006-2568455	20061117
AU 2006249270	A1	20070628	AU 2006-249270	20061208
JP 2007160092	A	20070628	JP 2006-332282	20061208
US 2007154530	A1	20070705	US 2006-608553	20061208
PRIORITY APPLN. INFO.:			GB 2005-25130	A 20051209

AB This invention relates to wound dressing composition comprising a human
recombinant collagen and an oxidized cellulose. For example, the composition
may be in the form of a sponge formed by freeze drying an aqueous dispersion
of human recombinant Collagen and oxidized regenerated cellulose (ORC).
The composition is especially suitable for the treatment of chronic wounds.

L2 ANSWER 2 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1145338 CAPLUS
DOCUMENT NUMBER: 145:460637
TITLE: Photostable wound dressing materials comprising silver
ions and methods of production thereof

INVENTOR(S): Cullen, Breda Mary; Silcock, Derek Walter; Boyle, James
 PATENT ASSIGNEE(S): Ethicon Inc., USA
 SOURCE: Brit. UK Pat. Appl., 25pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2425474	A	20061101	GB 2005-8431	20050426
AU 2006239065	A1	20061102	AU 2006-239065	20060316
WO 2006114565	A1	20061102	WO 2006-GB935	20060316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1874363	A1	20080109	EP 2006-710097	20060316
R: DE, FR, GB, IT, NL				
PRIORITY APPLN. INFO.:			GB 2005-8431	A 20050426
			WO 2006-GB935	W 20060316

AB A method of preparing an antimicrobial sponge material for medicinal use, comprising the steps of: (i) treating an anionic polysaccharide, which in one embodiment consists essentially of oxidized regenerated cellulose (ORC), with a solution of silver salt to produce a complex of the anionic polysaccharide with silver; and (ii) dispersing the complex in aqueous ascorbic acid to form an acidified dispersion, followed by freeze-drying or solvent-drying the dispersion to form the sponge material. Also provided is a photostabilized antimicrobial sponge material comprising an anionic polysaccharide complexed with silver(I) ions, wherein the sponge material further comprises ascorbate, and the sponge material has a substantially white color that is substantially stable against discoloration on exposure to light. Also provided is a wound dressing comprising such sponge material, the wound dressing in one embodiment further being sterile and packaged in a microorganism-impermeable container, and the use of ascorbic acid in an antimicrobial material comprising silver(I) salt to stabilize the material against discoloration on exposure to light.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2005:1350048 CAPLUS
 TITLE: Wound dressings for vacuum therapy
 INVENTOR(S): Watt, Paul William; Gregory, Sara Jayne; Trotter, Patrick John; Silcock, Derek Walter; Marsden, Donald Christopher
 PATENT ASSIGNEE(S): Ethicon, Inc., USA
 SOURCE: PCT Int. Appl.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005123170	A1	20051229	WO 2005-GB2423	20050620
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2415382	A	20051228	GB 2004-13867	20040621
EP 1758637	A1	20070307	EP 2005-755604	20050620
R: DE, ES, FR, GB, IT				
US 2007225663	A1	20070927	US 2006-609964	20061213
PRIORITY APPLN. INFO.:				
			GB 2004-13867	A 20040621
			WO 2005-GB2423	W 20050620

AB A wound dressing for vacuum therapy comprising: a cover configured for placement over the wound to maintain a reduced pressure over the wound and adapted for communication with a source of vacuum, and a screen structure for placement between the cover and the wound, wherein the screen structure is adapted to remove or inactivate undesirable components from the wound environment and/or to concentrate desirable components present; in the wound environment. Also provided are kits for the assembly of such wound dressings, and systems comprising the wound dressings in combination with a source of vacuum.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 4 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:172428 CAPLUS

DOCUMENT NUMBER: 142:246279

TITLE: Charcoal wound dressings coated with a water-insoluble polymer

INVENTOR(S): Silcock, Derek; Latif, Aisha

PATENT ASSIGNEE(S): Johnson & Johnson Medical

Limited, UK

SOURCE: Brit. UK Pat. Appl., 12 pp.

CODEN: BAXXDU

DOCUMENT TYPE:

Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2405343	A	20050302	GB 2003-20299	20030829
WO 2005021057	A1	20050310	WO 2004-GB3686	20040827
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,				

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG

GB 2420286 A 20060524 GB 2006-2025 20040827
 GB 2420286 B 20070905

PRIORITY APPLN. INFO.: GB 2003-20299 A 20030829
 WO 2004-GB3686 W 20040827

AB A wound dressing material comprising a charcoal cloth wherein the charcoal is coated with a substantially water-insol. polymer. Also provided are wound dressings comprising such materials, and methods of preparing such materials comprising the steps of impregnating a charcoal cloth with a dispersion of a polymer or polymer precursor in a solvent, followed by drying the charcoal cloth to leave a coating of the water-insol. polymer on the charcoal cloth. A silver-containing charcoal cloth was dipped in a solution of 0.5% chitosan in 2% acetic acid, removed, and air dried at 37°C. The treated cloth was then dipped in a 1% solution of NaOH in methanol to render the chitosan insol. in water. The coated charcoal cloth was then washed thoroughly with hot water followed by cold water. The final weight ratio of chitosan to charcoal cloth was about 0.2:1. The resulting cloth had appearance, liquid absorbency and odor absorbency similar to the untreated charcoal cloth, but tended to shed fewer particles.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 5 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:780568 CAPLUS

DOCUMENT NUMBER: 141:266085

TITLE: Hydrocolloid materials for use in wound healing

INVENTOR(S): Silcock, Derek Walter; Delbono, Michelle

PATENT ASSIGNEE(S): Johnson & Johnson Medical

Limited, UK

SOURCE: PCT Int. Appl., 17 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004080500	A1	20040923	WO 2004-GB892	20040303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2399289	A	20040915	GB 2003-5454	20030310
GB 2399289	B	20060308		
EP 1601388	A1	20051207	EP 2004-716655	20040303
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK				

US 2007020318	A1	20070125	US 2006-548231	20060818
PRIORITY APPLN. INFO.:			GB 2003-5454	A 20030310
			US 2003-458383P	P 20030331
			WO 2004-GB892	W 20040303

AB A wound dressing material comprising a low-moisture hydrocolloid matrix having oxidized cellulose distributed therein, for example, a matrix of dried sodium CM-cellulose gel having fibers of oxidized regenerated cellulose dispersed therein. Also provided are the use of such materials in the treatment of wounds, and the manufacture of such materials by drying aqueous

gels containing dispersed particles of oxidized cellulose.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 6 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:749519 CAPLUS

DOCUMENT NUMBER: 141:248807

TITLE: Hydrogel wound dressing with oxidized cellulose fibers

INVENTOR(S): Silcock, Derek Walter; Delbono, Michelle

PATENT ASSIGNEE(S): Johnson & Johnson Medical

Limited, UK

SOURCE: Brit. UK Pat. Appl., 14 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
GB 2399289	A	20040915	GB 2003-5454	20030310
GB 2399289	B	20060308		
WO 2004080500	A1	20040923	WO 2004-GB892	20040303
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

EP 1601388	A1	20051207	EP 2004-716655	20040303
------------	----	----------	----------------	----------

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK

US 2007020318	A1	20070125	US 2006-548231	20060818
---------------	----	----------	----------------	----------

PRIORITY APPLN. INFO.:

GB 2003-5454	A 20030310
--------------	------------

US 2003-458383P	P 20030331
-----------------	------------

WO 2004-GB892	W 20040303
---------------	------------

AB A wound dressing material comprising a low-moisture hydrogel matrix having oxidized cellulose distributed therein is described. For example, a matrix of dried sodium CM-cellulose gel having fibers of oxidized regenerated cellulose dispersed therein. Also provided are the use of such materials in the treatment of wounds, and the manufacture of such materials by drying aqueous gels containing dispersed particles of oxidized cellulose. The hydrogel may comprise modified celluloses or starches, alginates, plant gums, gelatins, glycosaminoglycans, polyacrylates or polyurethanes, with suitable plasticizers. For example, milled oxidized regenerated cellulose (ORC) fibers were dispersed at a concentration of 2.17%

by

weight in KY Jelly. The resulting gel was spread in a petri dish to a depth of 5 mm and dried in air at 37° for 48 h. The dried hydrogel layer obtained was flexible, conformable, and slightly elastic. The ORC in the hydrogel matrix appeared to be completely stable for at least 6 wk at 37° at ambient atmospheric

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 7 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:482249 CAPLUS

DOCUMENT NUMBER: 141:42986

TITLE: Absorbent multilayer hydrogel wound dressings comprising a flexible plasticized hydrophilic polymer matrix

INVENTOR(S): Munro, Hugh Semple; Hoskins, Richard; Garcia, Susana Sainz; Burgess, Helen; Barnes, Justin; Silcock, Derek; Bayliff, Simon William

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: Brit. UK Pat. Appl., 44 pp.
CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2396109	A	20040616	GB 2002-29024	20021212
GB 2396109	B	20060419		
WO 2004052414	A1	20040624	WO 2003-GB5460	20031212
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003294121	A1	20040630	AU 2003-294121	20031212
EP 1569698	A1	20050907	EP 2003-789541	20031212
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2006200063	A1	20060907	US 2006-538427	20060404
PRIORITY APPLN. INFO.:			GB 2002-29024	A 20021212
			WO 2003-GB5460	W 20031212

AB A wound dressing comprises an absorbent hydrogel composition comprising a foam portion which comprises a flexible plasticized hydrophilic polymer matrix having an internal cellular structure, and a continuous portion which comprises a flexible plasticized hydrophilic polymer matrix having relatively continuous internal structure. The continuous portion of the hydrogel composition includes apertures providing fluid flow communication through the continuous portion between an external surface of the continuous portion and the foam portion whereby the foam portion can take up external water or other fluid into the cellular structure through the apertures of the continuous portion. The continuous portion of the hydrogel composition may be tacky to the skin, allowing its use as a bioadhesive. Also claimed is a hydrogel composition for the preparation of a dressing for the treatment of wounds and burns. A composition was prepared from

Na 2-acrylamido-2-methylpropanesulfonate and N,N,N-trimethylammonioethyl acrylate chloride, water, polyoxyethylene-polyoxypropylene, and Daracure 1173.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 8 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:290453 CAPLUS

DOCUMENT NUMBER: 140:309491

TITLE: Wound treatment device

INVENTOR(S): Addison, Deborah; Essler, Alicia Joanna; Cullen, Breda Mary; Silcock, Derek Walter

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: PCT Int. Appl., 19 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028423	A1	20040408	WO 2003-GB4118	20030925
W:			AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW	
RW:			GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG	
GB 2393655	A	20040407	GB 2002-22527	20020927
GB 2393655	B	20050824		
AU 2003267624	A1	20040419	AU 2003-267624	20030925
EP 1542632	A1	20050622	EP 2003-748316	20030925
R:			AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK	
US 2006111657	A1	20060525	US 2005-528742	20051006
PRIORITY APPLN. INFO.:			GB 2002-22527	A 20020927
			US 2003-486445P	P 20030714
			WO 2003-GB4118	W 20030925

AB A wound treatment device comprises a water-impermeable envelope having at least one aperture, wherein the envelope contains a therapeutic substance, and wherein the at least one aperture in the envelope is blocked by a material that breaks down in the presence of one or more active components of wound fluid thereby permitting the therapeutic substance to contact the wound fluid. Preferably, the aperture is blocked by a material that is a substrate for an enzyme present in wound fluid, such as a protease. A device was prepared having an aperture of a sheet occluded by a thin film of Type I collagen.

L2 ANSWER 9 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:282763 CAPLUS

DOCUMENT NUMBER: 140:309375

TITLE: Wound dressing with controlled release of therapeutic agent

INVENTOR(S): Trotter, Patrick John; Silcock, Derek

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: Brit. UK Pat. Appl., 24 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2393656	A	20040407	GB 2002-22722	20021001
GB 2393656	B	20051116		
WO 2004030711	A1	20040415	WO 2003-GB4250	20031001
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003299184	A1	20040423	AU 2003-299184	20031001
EP 1545637	A1	20050629	EP 2003-756550	20031001
EP 1545637	B1	20060802		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
AT 334705	T	20060815	AT 2003-756550	20031001
US 2006269590	A1	20061130	US 2005-529157	20051013
PRIORITY APPLN. INFO.:			GB 2002-22722	A 20021001
			WO 2003-GB4250	W 20031001

AB A wound dressing comprises a therapeutic agent (e.g. antibiotic, antiseptic or analgesic) and a matrix of a polymer cross-linked by oligopeptidic sequences which are cleavable by a protease associated with wound fluid (e.g. through infection or ulcer formation) whereby release of the agent increases in the presence of the protease. The polymer may be natural or synthetic (e.g. poly N-(2-hydroxypropyl)-methacrylamide) and should be non-toxic and non-immunogenic.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 10 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:240130 CAPLUS

DOCUMENT NUMBER: 140:276154

TITLE: Wound dressing compositions comprising chitosan and oxidized regenerated cellulose and use for chronic wound treatment

INVENTOR(S): Cullen, Breda Mary; Silcock, Derek Walter

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: Brit. UK Pat. Appl., 28 pp.
 CODEN: BAXXDU

DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2393120	A	20040324	GB 2002-21688	20020918
CA 2499498	A1	20040401	CA 2003-2499498	20030917

WO 2004026200 A2 20040401 WO 2003-GB4019 20030917
 WO 2004026200 A3 20040902
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
 GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
 OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
 TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003264890 A1 20040408 AU 2003-264890 20030917
 EP 1539258 A2 20050615 EP 2003-797383 20030917
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006514843 T 20060518 JP 2004-537288 20030917
 US 2006172000 A1 20060803 US 2005-528262 20051118
 PRIORITY APPLN. INFO.: GB 2002-21688 A 20020918
 WO 2003-GB4019 W 20030917

AB The present invention relates to a wound dressing composition comprising a chitosan and an oxidized regenerated cellulose and its use for wound treatment. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of chitosan and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of chronic wounds. A method of separating cell growth factors from a biol. sample or organism using the composition is also outlined.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 11 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:454018 CAPLUS
 DOCUMENT NUMBER: 139:26648
 TITLE: Controlled release therapeutic wound dressings
 INVENTOR(S): Cullen, Breda Mary; Silcock, Derek; Warrick, Jonathan
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: Brit. UK Pat. Appl., 18 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2382775	A	20030611	GB 2001-29292	20011206
GB 2382775	B	20050525		
WO 2003047643	A1	20030612	WO 2002-GB5522	20021206
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002347354	A1	20030617	AU 2002-347354	20021206

EP 1463539 A1 20041006 EP 2002-783289 20021206
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK
 JP 2005511147 T 20050428 JP 2003-548897 20021206
 US 2005159695 A1 20050721 US 2005-497442 20050303
 PRIORITY APPLN. INFO.: GB 2001-29292 A 20011206
 WO 2002-GB5522 W 20021206

AB A wound dressing comprising: a therapeutic agent selected from the group consisting of antimicrobial substances, pain relieving substances, protease inhibitors, and mixts. thereof; and a barrier layer for initially separating the therapeutic agent from a wound fluid in use, wherein the barrier layer comprises a substrate for an enzyme selected from the group consisting of proteases, kallikrein and tissue-plasminogen activator. Preferably the substrate comprises a substrate for elastase or a collagenase. The barrier layer breaks down in infected or chronic wounds, thereby releasing the therapeutic substance selectively into such wounds.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 12 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:414272 CAPLUS
 DOCUMENT NUMBER: 139:12350
 TITLE: Absorbent wound dressings containing a hydrogel layer
 INVENTOR(S): Silcock, Derek; Kirkwood, Andrew James
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: Brit. UK Pat. Appl., 16 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2382305	A	20030528	GB 2001-28152	20011123
GB 2382305	B	20041215		
CA 2466678	A1	20030605	CA 2002-2466678	20021122
WO 2003045294	A1	20030605	WO 2002-GB5253	20021122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002365308	A1	20030610	AU 2002-365308	20021122
AU 2002365308	B2	20070705		
EP 1455701	A1	20040915	EP 2002-803863	20021122
EP 1455701	B1	20060308		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
JP 2005510296	T	20050421	JP 2003-546799	20021122
HU 2004002134	A2	20050628	HU 2004-2134	20021122
HU 225557	B1	20070328		
AT 319397	T	20060315	AT 2002-803863	20021122
ES 2260518	T3	20061101	ES 2002-2803863	20021122
US 2005256437	A1	20051117	US 2004-496158	20041104

PRIORITY APPLN. INFO.:

GB 2001-28152

A 20011123

WO 2002-GB5253

W 20021122

AB A wound dressing comprises a liquid-permeable top sheet having a wound facing surface and a back surface, the top sheet being adapted to block or restrict passage of liquid from the back surface to the wound facing surface; and a hydrogel layer adjacent to the back surface of the top sheet. The hydrogel layer comprises a hydrogel material selected from polyurethane gels, biopolymer gels, CM-cellulose gels, hydroxyethyl cellulose gels hydroxypropyl Me cellulose, modified acrylamides and mixts. thereof.

REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> display cost

ENTER COST FORMAT (ON):

ENTER COST FORMAT (ON):exit

'EXIT' IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY COST".

ENTER COST FORMAT (ON):quit

'QUIT' IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY COST".

ENTER COST FORMAT (ON):4

'4' IS NOT VALID HERE

For an explanation, enter "HELP DISPLAY COST".

ENTER COST FORMAT (ON):help display cost

Cost format must be specified by ON, BRIEF or FULL. With the ON cost format, the cost for the current file and total cost for the session will be displayed. The BRIEF format includes a detailed summary for the current file, a summary of the total session by file and cost center, and total cost for each cost center. The most detailed format, FULL, includes everything in the BRIEF format plus detailed cost for each file entered in the session. All costs are estimated and displayed in your billing currency.

ENTER COST FORMAT (ON):on

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

CONNECT CHARGES

9.66

9.81

NETWORK CHARGES

1.38

1.44

SEARCH CHARGES

12.72

12.72

DISPLAY CHARGES

34.92

34.92

FULL ESTIMATED COST

58.68

58.89

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-9.60

-9.60

IN FILE 'CAPLUS' AT 16:19:47 ON 15 JAN 2008

=> dup rem

ENTER L# LIST OR (END):12

PROCESSING COMPLETED FOR L2

L3 26 DUP REM L2 (0 DUPLICATES REMOVED)

=> d 13 13-26 ibib ab

L3 ANSWER 13 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:777749 CAPLUS

DOCUMENT NUMBER: 137:284370

TITLE: Peptides for the treatment of wound contracture
 INVENTOR(S): Cullen, Breda Mary; Silcock, Derek Walter
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: PCT Int. Appl., 14 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078728	A2	20021010	WO 2002-GB1173	20020326
WO 2002078728	A3	20030417		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2373724	A	20021002	GB 2001-7761	20010328
GB 2373724	B	20050202		
AU 2002241098	A1	20021015	AU 2002-241098	20020326
EP 1372693	A2	20040102	EP 2002-706935	20020326
EP 1372693	B1	20060614		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523591	T	20040805	JP 2002-576993	20020326
AT 329609	T	20060715	AT 2002-706935	20020326
PRIORITY APPLN. INFO.:			GB 2001-7761	A 20010328
			WO 2002-GB1173	W 20020326

OTHER SOURCE(S): MARPAT 137:284370

AB The present invention provides the use of a peptide derivative having the
 sequence X-NH-Gly-Pro-Ala-Gly-CO-Y, wherein X is H or a pharmaceutically
 acceptable N-terminal group, and Y is OH or a pharmaceutically acceptable
 C-terminal group, for the preparation of a medicament for use in the treatment
 or prevention of wound contracture.

L3 ANSWER 14 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:465856 CAPLUS
 DOCUMENT NUMBER: 137:37730
 TITLE: Dressings for the treatment of exuding wounds
 INVENTOR(S): Silcock, Derek; Marsden, Donald Christopher
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: PCT Int. Appl., 25 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002047737	A1	20020620	WO 2001-GB5466	20011211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				

CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
 GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 GB 2369997 A 20020619 GB 2000-30308 20001212
 GB 2369997 B 20040811
 AU 200222161 A 20020624 AU 2002-22161 20011211
 EP 1341561 A1 20030910 EP 2001-270350 20011211
 EP 1341561 B1 20070207
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004515319 T 20040527 JP 2002-549305 20011211
 AT 353228 T 20070215 AT 2001-270350 20011211
 ES 2279788 T3 20070901 ES 2001-1270350 20011211
 PRIORITY APPLN. INFO.: GB 2000-30308 A 20001212
 WO 2001-GB5466 W 20011211

AB The invention provides a layered wound dressing material comprising: a wound facing hydrogel layer and a barrier layer, wherein the barrier layer comprises a pH-sensitive material that is substantially insol. in water at 25°C under acidic conditions, but substantially soluble in water at 25°C under neutral or alkaline conditions. In use, the hydrogel layer absorbs and is gradually neutralized by wound exudate until its pH rises to a level that causes dissoln. of the barrier layer, thereby allowing excess exudate to flow out from the hydrogen layer. The invention further provides wound dressings comprising such barrier layers and methods of use of such dressings.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 15 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2002:368254 CAPLUS
 DOCUMENT NUMBER: 136:374945
 TITLE: Hydrogel wound dressings
 INVENTOR(S): Addison, Deborah; Silcock, Derek Walter
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: PCT Int. Appl., 21 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002038097	A1	20020516	WO 2001-GB4983	20011112
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002012552	A5	20020521	AU 2002-12552	20011112
EP 1333788	A1	20030813	EP 2001-980764	20011112

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
 JP 2004520096 T 20040708 JP 2002-540687 20011112
 TW 590763 B 20040611 TW 2001-90128043 20011113
 PRIORITY APPLN. INFO.: GB 2000-27674 A 20001113
 WO 2001-GB4983 W 20011112

AB The invention provides a wound dressing comprising: a liquid-permeable top sheet having a wound facing surface and a back surface, said top sheet being adapted to block or restrict passage of liquid from the back surface to the wound facing surface; and an insol. hydrogel layer on the wound facing surface of the top sheet. The hydrogel layer may comprise cellulose derivs., vinyl monomers, polyoxyalkylenes, etc.

REFERENCE COUNT: 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 16 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:785992 CAPLUS

DOCUMENT NUMBER: 139:73980

TITLE: The role of oxidized regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing

AUTHOR(S): Hart, Jeffrey; Silcock, Derek; Gunnigle, Stephen; Cullen, Breda; Light, Nicholas D.; Watt, Paul W.

CORPORATE SOURCE: St. James's University Hospital, Molecular Medicine Unit, Wound Repair Programme, University of Leeds, Leeds, LS9 7TF, UK

SOURCE: International Journal of Biochemistry & Cell Biology

(2002), 34(12), 1557-1570

CODEN: IJBBFU; ISSN: 1357-2725

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Irresp. of underlying chronic wound pathol., delayed wound healing is normally characterized by impaired new tissue formation at the site of injury. It is thought that this impairment reflects both a reduced capacity to synthesize new tissue and the antagonistic activities of high levels of proteinases within the chronic wound environment. Historically, wound dressings have largely been passive devices that offer the wound interim barrier function and establish a moist healing environment. A new generation of devices, designed to interact with the wound and promote new tissue formation, is currently being developed and tested. This study considers one such device, oxidized regenerated cellulose (ORC) /collagen, in terms of its ability to promote fibroblast migration and proliferation in vitro and to accelerate wound repair in the diabetic mouse, a model of delayed wound healing. ORC/collagen was found to promote both human dermal fibroblasts proliferation and cell migration. In vivo studies considered the closure and histol. characteristics of diabetic wounds treated with ORC/collagen compared to those of wounds given standard treatment on both diabetic and non-diabetic mice. ORC/collagen was found to significantly accelerate diabetic wound closure and result in a measurable improvement in the histol. appearance of wound tissues. As the diabetic mouse is a recognized model of impaired healing, which may share some characteristics of human chronic wounds, the results of this in vivo study, taken together with those relating the pos. effects of ORC/collagen in vitro, may predict the beneficial use of this device in the clin. setting.

REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 17 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:785991 CAPLUS
 DOCUMENT NUMBER: 139:73979
 TITLE: The role of oxidized regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action
 AUTHOR(S): Cullen, Breda; Watt, Paul W.; Lundqvist, Charlotte; Silcock, Derek; Schmidt, Richard J.; Bogan, Declan; Light, Nicholas D.
 CORPORATE SOURCE: Johnson & Johnson Wound Management, R&D Department, Division of ETHICON, Gargrave, BD23 3RX, UK
 SOURCE: International Journal of Biochemistry & Cell Biology (2002), 34(12), 1544-1556
 CODEN: IJBBFU; ISSN: 1357-2725
 PUBLISHER: Elsevier Science Ltd.
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Normal wound healing is a carefully controlled balance of destructive processes necessary to remove damaged tissue and repair processes which lead to new tissue formation. Proteases and growth factors play a pivotal role in regulating this balance, and if disrupted in favor of degradation then delayed healing ensues; a trait of chronic wounds. While there are many types of chronic wounds, biochem. they are thought to be similar in that they are characterized by a prolonged inflammatory phase, which results in elevated levels of proteases and diminished growth factor activity. This increase in proteolytic activity and subsequent degradation of growth factors is thought to contribute to the net tissue loss associated with these chronic wounds. In this study, we describe a new wound treatment, comprising oxidized regenerated cellulose and collagen (ORC/collagen), which can redress this imbalance and modify the chronic wound environment. We demonstrate that ORC/collagen can inactivate potentially harmful factors such as proteases, oxygen free radicals and excess metal ions present in chronic wound fluid, while simultaneously protecting pos. factors such as growth factors and delivering them back to the wound. These characteristics suggest a beneficial role for this material in helping to re-balance the chronic wound environment and therefore promote healing.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 18 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:265287 CAPLUS
 DOCUMENT NUMBER: 134:271294
 TITLE: Oxidized cellulose for the treatment of wound contracture
 INVENTOR(S): Cullen, Breda Mary; Silcock, Derek Walter
 PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK
 SOURCE: PCT Int. Appl., 15 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024841	A1	20010412	WO 2000-GB3744	20000929
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,			

LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU,
 SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN,
 YU, ZA, ZW
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 GB 2354708 A 20010404 GB 1999-23291 19991001
 GB 2354708 B 20040602
 EP 1216066 A1 20020626 EP 2000-964446 20000929
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 JP 2003511099 T 20030325 JP 2001-527840 20000929
 PRIORITY APPLN. INFO.: GB 1999-23291 A 19991001
 WO 2000-GB3744 W 20000929

AB The present invention provides the use of an oxidized cellulose for the
 preparation of a medicament for use in the treatment or prevention of wound
 contracture. Preferably, the oxidized cellulose is oxidized regenerated
 cellulose (ORC) or partially hydrolyzed ORC. Preparation of soluble hydrolyzed
 ORC from Surgicel was described. Formulation of an ointment containing 2%
 hydrolyzed ORC disclosed.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 19 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2001:136964 CAPLUS
 DOCUMENT NUMBER: 134:183548
 TITLE: Easy to remove adhesive sheets for use in a wound
 dressing
 INVENTOR(S): Patel, Dharmendra; Silcock, Derek; Cullen, Breda;
 Lowing, Paul Howard
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: PCT Int. Appl., 16 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012116	A1	20010222	WO 2000-GB3146	20000815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2353219	A	20010221	GB 1999-19368	19990816
GB 2353219	B	20040211		
EP 1204391	A1	20020515	EP 2000-953325	20000815
EP 1204391	B1	20041013		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003506197	T	20030218	JP 2001-516463	20000815
PRIORITY APPLN. INFO.:			GB 1999-19368	A 19990816
			WO 2000-GB3146	W 20000815

AB The invention provides an adhesive sheet for use in a wound dressing or

the like, comprising: a backing layer; a layer of adhesive applied to a first side of the backing layer for adhering the adhesive sheet to a surface; and an elongate conduit for a fluid provided in or on said first side of the backing layer, wherein the conduit is provided with an inlet for introducing fluid into the conduit while the adhesive sheet is adhered to the surface to assist removal of the adhesive sheet from the surface. The invention also provides a similar adhesive sheet in which the elongate conduit is replaced by an elongate reservoir containing a liquid release agent, wherein the reservoir can be ruptured to release the liquid therefrom into the adhesive layer while the adhesive sheet is adhered to the surface to assist removal of the adhesive sheet from the surface. A bottom plan view of an island-type wound dressing incorporating an adhesive sheet according to the present invention is depicted (no data).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 20 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:466455 CAPLUS

DOCUMENT NUMBER: 135:241469

TITLE: Does nitrogen addition to raised bogs influence peat phosphorus pools?

AUTHOR(S): Williams, B. L.; Silcock, D. J.

CORPORATE SOURCE: Macaulay Land Use Research Institute, Aberdeen, AB15 8QH, UK

SOURCE: Biogeochemistry (2001), 53(3), 307-321

CODEN: BIOGEP; ISSN: 0168-2563

PUBLISHER: Kluwer Academic Publishers

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Two Sphagnum moss species occupying hummock areas (*Sphagnum capillifolium*) and wetter hollows (*Sphagnum recurvum*) on a raised bog in north east Scotland were treated every two weeks with NH_4NO_3 solns. to supply 3 g N m^{-2} yr^{-1} . Although *S. recurvum* moss contained a greater concentration of total P

than *S. capillifolium* the amts. and N:P ratios were similar in both species. Larger amts. of total dissolved P (TDP) and molybdate-reactive P (MRP) were extracted from beneath *S. recurvum* to 25 cm below the moss. Addns. of N both increased and decreased the amts. of TDP at different times, and decreased MRP. The MRP fraction accounted for 20 % of TDP and the difference was assumed to be in organic forms (DOP). Nitrogen addition had no effect on the amts. of DOP, but C:P ratios of this fraction changed with species, depth and N addition. Microbial P accounted for as much as 70 per cent of total P and showed seasonal variations, but no differences between the two moss species and N addition

REFERENCE COUNT: 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 21 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:401694 CAPLUS

DOCUMENT NUMBER: 133:34483

TITLE: Sterile complex of therapeutic peptide bonded to a polysaccharide

INVENTOR(S): Cullen, Breda; Silcock, Derek; Van Leeuwen, Peter; Harvey, Wilson

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: PCT Int. Appl., 41 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033893	A1	20000615	WO 1999-GB4094	19991206
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
GB 2344519	A	20000614	GB 1998-26897	19981207
GB 2344519	B	20040519		
CA 2319327	A1	20000615	CA 1999-2319327	19991206
BR 9907679	A	20001024	BR 1999-7679	19991206
EP 1053029	A1	20001122	EP 1999-958396	19991206
EP 1053029	B1	20030910		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
SI 20306	A	20010228	SI 1999-20021	19991206
JP 2002531532	T	20020924	JP 2000-586383	19991206
AT 249249	T	20030915	AT 1999-958396	19991206
AU 771733	B2	20040401	AU 2000-15770	19991206
IN 2000KN00137	A	20050311	IN 2000-KN137	20000714
HK 1032362	A1	20040130	HK 2001-102883	20010423
PRIORITY APPLN. INFO.:			GB 1998-26897	A 19981207
			WO 1999-GB4094	W 19991206

AB The invention provides sterile compns. comprising a complex of a therapeutic peptide and a polysaccharide selected from the group consisting of cellulose derivs., chitin, chitosans, galactomannans, and mixts. thereof, wherein the complex has been sterilized with ionizing radiation. The presence of the polysaccharides surprisingly stabilizes therapeutic peptides against decomposition under ionizing conditions, especially under gamma-irradiation Processes for the preparation of the sterile compns. and processes for the preparation of sterile therapeutic peptides are also claimed. For example, a sterile pharmaceutical gel for topical administration to promote wound healing was formulated containing CM-cellulose 2.4, hydroxyethyl cellulose 0.3, NaCl 0.24, propylene glycol 20.2, collagen/oxidized regenerated cellulose/platelet-derived growth factor (1 weight%) 2.0, and water up to 100%, resp.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 22 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 1997:595454 CAPLUS
 DOCUMENT NUMBER: 127:205028
 TITLE: Nutrient and microbial changes in the peat profile beneath Sphagnum magellanicum in response to additions of ammonium nitrate
 AUTHOR(S): Williams, B. L.; Silcock, D. J.
 CORPORATE SOURCE: Macaulay Land Use Res. Inst., Craigiebuckler/Aberdeen, AB15 8QH, UK
 SOURCE: Journal of Applied Ecology (1997), 34(4), 961-970
 CODEN: JAPEAI; ISSN: 0021-8901
 PUBLISHER: Blackwell
 DOCUMENT TYPE: Journal
 LANGUAGE: English

AB Applications of ammonium nitrate (NH₄NO₃) to cores of *Sphagnum magellanicum* in situ at 2-wk intervals for 20 wk from mid-June at a raised mire in north-east Scotland stimulated growth at only 1 g N m⁻² year⁻¹, whereas greater addns., equivalent to 3 and 10 g N m⁻², had no significant effect. The N concentration of the moss tissues increased linearly with increasing levels of NH₄NO₃ up to 10 g N m⁻² year⁻¹. In cores receiving an addition of 10 g N m⁻² year⁻¹, there was a significant increase in the concentration of organic N extracted from the moss in the surface 5 cm with 0.5M K₂SO₄.

The concentration of organic N correlated linearly with the quantity of N applied.

NH₄NO₃ significantly reduced the rate of CO₂ evolved from samples from a depth of 5-10 cm, and increased microbial C as measured by the substrate-induced respiration (SIR) method. Overall, inorg. addns. at 1 g N m⁻² year⁻¹ reduced the specific rate of respiration and activity of the microbial biomass at this depth. The mean total N:P ratios for the profile ranged from 24 to 28, suggesting that the site was P-deficient, which probably limited the growth response of *S. magellanicum*.

REFERENCE COUNT: 34 THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 23 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:180118 CAPLUS

DOCUMENT NUMBER: 126:259571

TITLE: The differential regulation and secretion of proteinases from fetal and neonatal fibroblasts by growth factors

AUTHOR(S): Cullen, Breda; Silcock, Derek; Brown, Laura J.; Gosiewska, Anna; Geesin, Jeffrey C.

CORPORATE SOURCE: Johnson and Johnson Wound Healing Technology Resource Center, Skillman, NJ, 08558-9418, USA

SOURCE: International Journal of Biochemistry

& Cell Biology

(1997), 29(1), 241-250

CODEN: IJBBFU; ISSN: 1357-2725

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB One of the major differences between fetal and adult wound repair is the unique ability of fetal wounds to heal without scarring. Since scar formation is a function of extracellular matrix deposition, the regulation of this component is fundamental in tissue remodeling. In this study, the authors have characterized the differences in the secretion of matrix-degrading proteases, namely urokinase plasminogen activator and gelatinase A and B, from fetal and neonatal fibroblasts. In addition, the authors examined the modulation of these protease levels by growth factors known to be important in wound repair. The results indicate that the secretion of these proteases differ significantly between the two cell types. The levels of urokinase plasminogen activator and its inhibitor were notably higher in media conditioned by neonatal fibroblasts in comparison to fetal samples. In contrast, the basal level of gelatinase A was comparable in both cell types, while the level of gelatinase B was elevated in the fetal fibroblasts. Transforming growth factor- β 1 reduced the level of urokinase plasminogen activator and stimulated the secretion of plasminogen activator inhibitor-1 and progelatinase B in both neonatal and fetal fibroblasts. However, only progelatinase A and an activated form of gelatinase B were significantly elevated in fetal fibroblasts. In contrast, platelet-derived growth factor stimulated urokinase plasminogen activator, its inhibitor and both gelatinase A and B, an effect which was more apparent in fetal fibroblasts. This difference in protease regulation may be reflected in the differing rate

and quality of tissue remodeling observed during adult vs. fetal wound repair.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 24 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:212343 CAPLUS

DOCUMENT NUMBER: 120:212343

TITLE: Construction and detection of bioluminescent strains of *Bacillus subtilis*

AUTHOR(S): Cook, N.; Silcock, D.J.; Waterhouse, R.N.; Prosser, J.I.; Glover, L.A.; Killham, K.

CORPORATE SOURCE: Marischal Coll., Univ. Aberdeen, Aberdeen, UK

SOURCE: Journal of Applied Bacteriology (1993), 75(4), 350-9
CODEN: JABAA4; ISSN: 0021-8847

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Bioluminescence (lux) genes from *Vibrio fischeri* and *V. harveyi* were introduced into *B. subtilis* on a plasmid vector and by chromosomal integration. The plasmid-bearing strain was highly luminescent and stable under antibiotic selection, but luminescence was lost in the absence of selection and following sporulation and germination. The chromosomally marked strains emitted less light but were stable without the requirement for antibiotic selection and following sporulation and germination. Individual luminescing colonies of both *B. subtilis* strains could be detected against a high background of non-bioluminescent indigenous soil microbial colonies on agar plates using a charge-coupled device camera. These bioluminescent Gram-pos. strains could be of value in studies concerning the survival and spread of genetically-modified microorganisms in soil environments.

L3 ANSWER 25 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1994:526272 CAPLUS

DOCUMENT NUMBER: 121:126272

TITLE: The cloning and characterization of phage promoters, directing high expression of luciferase in *Pseudomonas syringae* pv. *phaseolicola*, allowing single cell and microcolony detection

AUTHOR(S): Waterhouse, R. N.; Silcock, D. J.; White, H. L.; Buhariwalla, H. K.; Glover, L. A.

CORPORATE SOURCE: Dep. Mol. Cell Biol., Univ. Aberdeen, Aberdeen, AB9 1AS, UK

SOURCE: Molecular Ecology (1993), 2(5), 285-94
CODEN: MOECEO; ISSN: 0962-1083

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Regions of DNA containing promoter sequences from a *Pseudomonas syringae* pv. *phaseolicola*-specific phage (.vphi.11P) were identified by shotgun cloning into a broad-host-range promoter-probe vector (pQF70). When used in conjunction with the luciferase reporter genes, one of these DNA fragments, 19H, directed gene expression at a level which enabled the subsequent light output (bioluminescence) of single cells of *P. syringae* pv. *phaseolicola* to be detected and visualized using a charge-coupled device (CCD). The *P. syringae* pv. *phaseolicola* .vphi.11P, 19H and *P. aeruginosa* .vphi.PLS27, HcM promoters gave a 50-fold increase in bioluminescence (maximum relative light output) compared to similar constructs containing other well-characterized promoters, for example, tetracycline. Similar bioluminescent characteristics of the transformed bacterium, were observed during growth with and without antibiotic-selection. When lux+ bacteria were inoculated onto French bean leaf (*Phaseolus vulgaris* L.), the resultant secondary halo blight lesions were

bioluminescent and during phylloplane colonization by the lux+ bacterium, bioluminescence on leaf surfaces was detected and imaged by the CCD. Use of these newly identified promoters, combined with the greatly increased sensitivity of bioluminescence detection by the CCD, thus provided a new dimension for the study of natural ecol. populations during the bacterial colonization of plants.

L3 ANSWER 26 OF 26 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:475061 CAPLUS

DOCUMENT NUMBER: 113:75061

TITLE: Changes in nuclear DNA content, cell and nuclear size, and frequency of cell division in the cotyledons of *Brassica napus* L. during embryogenesis

AUTHOR(S): Silcock, D. J.; Francis, D.; Bryant, J. A.; Hughes, S. G.

CORPORATE SOURCE: Coll. Cardiff, Univ. Wales, Cardiff, CF1 3TL, UK

SOURCE: Journal of Experimental Botany (1990), 41(225), 401-7
CODEN: JEBOA6; ISSN: 0022-0957

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Cellular behavior was examined during embryogenesis in *B. napus* to test whether or not polyploidy occurs in the cotyledons during the phase of oil deposition. Nuclear DNA content, nuclear and cell size, and the mitotic index were measured in the cotyledons on various days post anthesis (dpa). In squashed monolayers from 15 dpa cotyledons, a polyploid (>5C) population was detected together with a substantial number of cells in G2 (4C). Nuclear volume was measured on sectioned tissues and, at 15 dpa, the range of values from the cotyledons (40-500 μm^3) contrasted with that in the vestigial suspensor and endosperm (50->600 μm^3). At 15 dpa the nuclear volume data suggest that while cells in the cotyledons were in G1 and G2 many endosperm and suspensor cells were polyploid. Thus, polyploidy observed in the squashed monolayers was probably due to contaminating endosperm/suspensor cells. At 25 and 35 dpa, polyploidy was not detected; all cells were in G1 (2C) and cell area increased. The mitotic index peaked at 20 dpa before declining and given the narrower distribution of nuclear vols. at 25 and 35 dpa (50-300 μm^3), these data are consistent with cell arrest in G1. Thus, polyploidy was not detected in the cotyledons of *B. napus* which differs from what is known about cellular development in legume cotyledons.

=> e breda cullen

E1	1	BRED2/BI
E2	82	BREDA/BI
E3	0 -->	BREDA CULLEN/BI
E4	1	BREDAC/BI
E5	1	BREDADENSIS/BI
E6	24	BREDANENSIS/BI
E7	21	BREDAS/BI
E8	2	BREDASDORP/BI
E9	1	BREDAVIRUS/BI
E10	3	BREDBERG/BI
E11	1	BREDBISSONII/BI
E12	1	BREDBO/BI

=> e cullen

E1	481	CULLED/BI
E2	1	CULLEDCOWS/BI
E3	236 -->	CULLEN/BI
E4	4	CULLENDER/BI
E5	3	CULLENIA/BI

E6	1	CULLENS/BI
E7	1	CULLEOKA/BI
E8	9	CULLER/BI
E9	7	CULLERA/BI
E10	1	CULLERTSONI/BI
E11	1470	CULLET/BI
E12	1	CULLETE/BI

=> e cullen breda

E1	1	CULLEDCOWS/BI
E2	236	CULLEN/BI
E3	0	--> CULLEN BREDA/BI
E4	4	CULLENDER/BI
E5	3	CULLENIA/BI
E6	1	CULLENS/BI
E7	1	CULLEOKA/BI
E8	9	CULLER/BI
E9	7	CULLERA/BI
E10	1	CULLERTSONI/BI
E11	1470	CULLET/BI
E12	1	CULLETE/BI

=> e cullen b

E1	1	CULLEDCOWS/BI
E2	236	CULLEN/BI
E3	0	--> CULLEN B/BI
E4	4	CULLENDER/BI
E5	3	CULLENIA/BI
E6	1	CULLENS/BI
E7	1	CULLEOKA/BI
E8	9	CULLER/BI
E9	7	CULLERA/BI
E10	1	CULLERTSONI/BI
E11	1470	CULLET/BI
E12	1	CULLETE/BI

=> e breda mary cullen

E1	1	BRED2/BI
E2	82	BREDA/BI
E3	0	--> BREDA MARY CULLEN/BI
E4	1	BREDAC/BI
E5	1	BREDADENSIS/BI
E6	24	BREDANENSIS/BI
E7	21	BREDAS/BI
E8	2	BREDASDORP/BI
E9	1	BREDAVIRUS/BI
E10	3	BREDBERG/BI
E11	1	BREDBISSONII/BI
E12	1	BREDBO/BI

=> e cullen, breda mary

E1	1	CULLEDCOWS/BI
E2	236	CULLEN/BI
E3	0	--> CULLEN, BREDA MARY/BI
E4	4	CULLENDER/BI
E5	3	CULLENIA/BI
E6	1	CULLENS/BI
E7	1	CULLEOKA/BI
E8	9	CULLER/BI
E9	7	CULLERA/BI
E10	1	CULLERTSONI/BI

E11 1470 CULLET/BI
E12 1 CULLETE/BI

=> expand cullen

ENTER FIELD CODE (BI):au

E1 8 CULLELL YOUNG M/AU
E2 1 CULLELL YOUNG MARTIN/AU
E3 1 --> CULLEN/AU
E4 2 CULLEN A/AU
E5 4 CULLEN A B/AU
E6 1 CULLEN A J/AU
E7 4 CULLEN A L/AU
E8 1 CULLEN A M/AU
E9 9 CULLEN A P/AU
E10 1 CULLEN AAARON J/AU
E11 1 CULLEN AARON BRADLEY/AU
E12 6 CULLEN AARON J/AU

=> expand cullen b

ENTER FIELD CODE (BI):au

E1 10 CULLEN ANTHONY P/AU
E2 1 CULLEN AOIFE A/AU
E3 10 --> CULLEN B/AU
E4 1 CULLEN B A/AU
E5 3 CULLEN B F/AU
E6 3 CULLEN B M/AU
E7 3 CULLEN B R/AU
E8 11 CULLEN BARRY A/AU
E9 1 CULLEN BEATRIZ DE TOLEDO/AU
E10 2 CULLEN BERNADETTE/AU
E11 1 CULLEN BERNARD/AU
E12 4 CULLEN BETSEY/AU

=> expand

ENTER TERM OR (CONTINUE):continue

E13 3 CULLEN BEULAH/AU
E14 6 CULLEN BEULAH M/AU
E15 1 CULLEN BILL/AU
E16 5 CULLEN BRED A/AU
E17 4 CULLEN BRED A M/AU
E18 27 CULLEN BRED A MARY/AU
E19 1 CULLEN BRENDAN R/AU
E20 24 CULLEN BRUCE F/AU
E21 3 CULLEN BRYAN/AU
E22 247 CULLEN BRYAN R/AU
E23 3 CULLEN BRYAN RICHARD/AU
E24 8 CULLEN C/AU

=> search e16 or e17 or e18

5 "CULLEN BRED A"/AU
4 "CULLEN BRED A M"/AU
27 "CULLEN BRED A MARY"/AU
L4 36 "CULLEN BRED A"/AU OR "CULLEN BRED A M"/AU OR "CULLEN BRED A MARY"/
AU

=> search l4 or l3

L5 26 S L3
L6 50 L4 OR L5

=> dup rem

ENTER L# LIST OR (END):16

PROCESSING COMPLETED FOR L6
L7 50 DUP REM L6 (0 DUPLICATES REMOVED)

=> display 14 1-36 ibib abs

L4 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:640559 CAPLUS
DOCUMENT NUMBER: 147:39279
TITLE: Wound dressings comprising oxidized cellulose and human recombinant collagen
INVENTOR(S): Boyle, Clare; Silcock, Derek Walter; Cullen, Breda Mary
PATENT ASSIGNEE(S): Ethicon, Inc., USA
SOURCE: Eur. Pat. Appl., 10pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 1795210	A2	20070613	EP 2006-256271	20061208
EP 1795210	A3	20070905		
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
GB 2433029	A	20070613	GB 2005-25130	20051209
CA 2568455	A1	20070609	CA 2006-2568455	20061117
AU 2006249270	A1	20070628	AU 2006-249270	20061208
JP 2007160092	A	20070628	JP 2006-332282	20061208
US 2007154530	A1	20070705	US 2006-608553	20061208
PRIORITY APPLN. INFO.:			GB 2005-25130	A 20051209

AB This invention relates to wound dressing composition comprising a human recombinant collagen and an oxidized cellulose. For example, the composition may be in the form of a sponge formed by freeze drying an aqueous dispersion of human recombinant Collagen and oxidized regenerated cellulose (ORC). The composition is especially suitable for the treatment of chronic wounds.

L4 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:273853 CAPLUS
DOCUMENT NUMBER: 146:271786
TITLE: Diagnostic markers of wound infection
INVENTOR(S): Clark, Rachael Louise; Cullen, Breda Mary
PATENT ASSIGNEE(S): Ethicon Inc., USA
SOURCE: Brit. UK Pat. Appl., 23pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2430031	A	20070314	GB 2005-18293	20050907
PRIORITY APPLN. INFO.:			GB 2005-18293	20050907

AB A method for the diagnosis or prognosis of wound infection comprises measuring the level of interleukin-4 (IL-4) in a sample of wound fluid. This method may be used to determine whether to treat a wound with anti-microbial or non-antimicrobial wound dressings. Devices, such as swabs and dressings, comprising a binding partner for IL-4, preferably an

antibody against IL-4, are used for this method.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:259970 CAPLUS
DOCUMENT NUMBER: 146:293234
TITLE: Use of angiogenic factors as diagnostic markers of
wound infection
INVENTOR(S): Clark, Rachael L.; Cullen, Breda Mary
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 10pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2007053961	A1	20070308	US 2006-516210	20060906
GB 2430029	A	20070314	GB 2005-18286	20050907
PRIORITY APPLN. INFO.:			GB 2005-18286	A 20050907

AB The present invention relates to a method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least on angiogenic factor in a sample of wound fluid. The preferred angiogenic growth factors are angiogenin and vascular endothelial growth factor (VEGF). The present invention also provides methods (e.g., immunoassay) and products for diagnosing and treating infected wounds.

L4 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:258947 CAPLUS
DOCUMENT NUMBER: 146:269782
TITLE: Diagnostic markers of wound infection
INVENTOR(S): Clark, Rachael L.; Cullen, Breda Mary
PATENT ASSIGNEE(S): UK
SOURCE: U.S. Pat. Appl. Publ., 10pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
US 2007053962	A1	20070308	US 2006-516212	20060906
GB 2430030	A	20070314	GB 2005-18288	20050907
PRIORITY APPLN. INFO.:			GB 2005-18288	A 20050907

AB The present invention relates to a method of diagnosis or prognosis of a mammalian wound infection, said method comprising the step of measuring the level of at least one cell surface receptor in a sample of wound fluid. The preferred cell surface receptors are Intercellular adhesion mol.-1 (ICAM 1) and Tumor Necrosis Factor Receptor-2 (TNF-RII). The present invention also provides devices (e.g. biosensors) for use in such methods, and methods and products for diagnosing and treating infected wounds.

L4 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2006:1222733 CAPLUS
DOCUMENT NUMBER: 145:501930

TITLE: Marker of wound infection and method for diagnosis
 INVENTOR(S): Cullen, Breda Mary; Clark, Rachael Louise
 PATENT ASSIGNEE(S): Ethicon Inc., USA
 SOURCE: Brit. UK Pat. Appl., 25pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2426335	A	20061122	GB 2005-10340	20050520
WO 2006123091	A1	20061123	WO 2006-GB1467	20060424
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

PRIORITY APPLN. INFO.: GB 2005-10340 A 20050520
 AB An indicator device adapted give a detectable signal when the antioxidant capacity of a sample of a mammalian wound fluid exceeds a predetd. min. level which is characteristic of an infected wound. Also provided system for use in the diagnosis and treatment of wounds comprising the inventive diagnostic device and a wound dressing comprising at least one antimicrobial agent for selective application to infected wounds. Also provided are methods of diagnosis and treatment by means of the inventive device and system.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:1145338 CAPLUS
 DOCUMENT NUMBER: 145:460637
 TITLE: Photostable wound dressing materials comprising silver ions and methods of production thereof
 INVENTOR(S): Cullen, Breda Mary; Silcock, Derek Walter; Boyle, James
 PATENT ASSIGNEE(S): Ethicon Inc., USA
 SOURCE: Brit. UK Pat. Appl., 25pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2425474	A	20061101	GB 2005-8431	20050426
AU 2006239065	A1	20061102	AU 2006-239065	20060316
WO 2006114565	A1	20061102	WO 2006-GB935	20060316
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR,				

KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX,
 MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE,
 SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC,
 VN, YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM

EP 1874363 A1 20080109 EP 2006-710097 20060316

R: DE, FR, GB, IT, NL

PRIORITY APPLN. INFO.:

GB 2005-8431 A 20050426

WO 2006-GB935 W 20060316

AB A method of preparing an antimicrobial sponge material for medicinal use, comprising the steps of: (i) treating an anionic polysaccharide, which in one embodiment consists essentially of oxidized regenerated cellulose (ORC), with a solution of silver salt to produce a complex of the anionic polysaccharide with silver; and (ii) dispersing the complex in aqueous ascorbic acid to form an acidified dispersion, followed by freeze-drying or solvent-drying the dispersion to form the sponge material. Also provided is a photostabilized antimicrobial sponge material comprising an anionic polysaccharide complexed with silver(I) ions, wherein the sponge material further comprises ascorbate, and the sponge material has a substantially white color that is substantially stable against discoloration on exposure to light. Also provided is a wound dressing comprising such sponge material, the wound dressing in one embodiment further being sterile and packaged in a microorganism-impermeable container, and the use of ascorbic acid in an antimicrobial material comprising silver(I) salt to stabilize the material against discoloration on exposure to light.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2006:261936 CAPLUS

DOCUMENT NUMBER: 144:318684

TITLE: Wound treatment system comprising an oxidized cellulose dressing

INVENTOR(S): Cullen, Breda Mary

PATENT ASSIGNEE(S): Ethicon Inc., USA

SOURCE: Brit. UK Pat. Appl., 25 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
GB 2418145	A	20060322	GB 2004-20774	20040917
WO 2006030232	A2	20060323	WO 2005-GB3585	20050916
WO 2006030232	A3	20060504		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
 NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
 YU, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,

CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2004-20774 A 20040917

AB A wound treatment system is provided comprising (i) a wound dressing comprising an oxidized cellulose, and (ii) a wound fluid anal. apparatus for measuring the concentration of at least one marker of chronic wound healing potential in a wound fluid, wherein said marker is selected from the group consisting of endogenous protease enzymes and endogenous protease enzyme inhibitors. Suitably the protease enzyme is neutrophil elastase and the protease enzyme inhibitor is α 1-antitrypsin. The apparatus for measuring the concentration of the marker may be a dip stick, test strip, or a swab. The oxidized cellulose may be oxidized regenerated cellulose (ORC) and may be combined with chitosan or collagen in the form of a woven or nonwoven fabric or a sponge.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1329741 CAPLUS

DOCUMENT NUMBER: 144:47666

TITLE: Measurement of cytoskeletal proteins and uses thereof in diagnosis, prognosis and therapy of inflammatory condition or wound infection

INVENTOR(S): Shah, Faraia; Clark, Rachael; Trotter, Patrick John; Watt, Paul William; Cullen, Breda Mary

PATENT ASSIGNEE(S): Ethicon, Inc., USA

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005121803	A1	20051222	WO 2005-GB2256	20050609
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US 2007141131 A1 20070621 US 2006-608906 20061211

PRIORITY APPLN. INFO.: GB 2004-13001 A 20040610

AB The present invention relates to monitoring patients for an inflammatory condition or infection (preferably wound infection) by testing an extracellular fluid such as a wound fluid for an elevated level of: (i) a cytoskeletal component, especially vimentin; (ii) a cytoskeletal component breakdown product, especially a vimentin breakdown product; or (iii) a marker indicative of the presence of a cytoskeletal component or of vimentin. The present invention provides methods of diagnosis and prognosis, wound dressings, devices (e.g. biosensors) and kits for use in such methods. Wound fluid from infected and noninfected patients were analyzed by Western blotting for vimentin. Higher levels of vimentin and a 40 kDa

breakdown product of vimentin were present in the infected fluid than in the noninfected fluid.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1328413 CAPLUS

DOCUMENT NUMBER: 144:47655

TITLE: Diagnosis and prognosis of wound infection by measurement of a phospholipase A2 in wound fluid

INVENTOR(S): Shah, Faraia; Clark, Rachael; Trotter, Patrick John; Watt, Paul William; Cullen, Breda Mary

PATENT ASSIGNEE(S): Ethicon, Inc., USA

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005121357	A2	20051222	WO 2005-GB2262	20050609
WO 2005121357	A3	20060601		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
GB 2415039	A	20051214	GB 2004-13078	20040611
CA 2569959	A1	20051222	CA 2005-2569959	20050609
EP 1756298	A2	20070228	EP 2005-748372	20050609
R:	DE, ES, FR, GB, IT			
PRIORITY APPLN. INFO.:			GB 2004-13078	A 20040611
			US 2004-625830P	P 20041108
			WO 2005-GB2262	W 20050609

AB The present invention relates to the diagnosis, prognosis and/or treatment of wound infection by testing wound fluid for the presence of a marker which is present in an amount which is indicative of infection. The marker may be high mol. weight phospholipase A2 (cPLA2) or a marker which is correlated with cPLA2. A wound dressing or biosensor comprising components of an assay system for testing wound fluid for the presence or level of cPLA2 or of a marker which is indicative of the presence or level of cPLA2 is used in diagnosis or prognosis of wound infection. A system comprises a diagnostic device, a wound dressing having at least one antimicrobial agent for application to the wound when the level indicates wound infection, and a wound dressing free of antimicrobial agents for application when the level indicates a non-infected wound. Wound fluid from non-infected and from infected patients were analyzed by Western blotting. No cPLA2 was observed in the noninfected patients and cPLA2 was present in four out of five infected patients.

L4 ANSWER 10 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1302895 CAPLUS

DOCUMENT NUMBER: 144:33833
 TITLE: Diagnosis of inflammatory conditions by testing for the presence of cytosolic phospholipase A2
 INVENTOR(S): Shah, Faraia; Clark, Rachael; Trotter, Patrick John; Watt, Paul William; Cullen, Breda Mary
 PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK
 SOURCE: Brit. UK Pat. Appl., 15 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2415039	A	20051214	GB 2004-13078	20040611
CA 2569959	A1	20051222	CA 2005-2569959	20050609
WO 2005121357	A2	20051222	WO 2005-GB2262	20050609
WO 2005121357	A3	20060601		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1756298	A2	20070228	EP 2005-748372	20050609
R: DE, ES, FR, GB, IT				
US 2007231380	A1	20071004	US 2006-608940	20061211
PRIORITY APPLN. INFO.:				
			GB 2004-13078	A 20040611
			US 2004-625830P	P 20041108
			WO 2005-GB2262	W 20050609

AB A method for the diagnosis or prognosis of inflammatory conditions comprises testing extracellular fluid for the presence or level of high mol. weight (cytosolic) phospholipase A2 (cPLA2) in extracellular fluid. The inflammatory condition may be wound infection, and the assay system may be incorporated in a biosensor or wound dressing. Alternatively, the inflammatory condition may be infection, psoriasis, cancer or cardiovascular disease.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 11 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:472009 CAPLUS
 DOCUMENT NUMBER: 143:13454
 TITLE: Antioxidant and antimicrobial wound dressing materials
 INVENTOR(S): Addison, Deborah; Greenhalgh, David; Cullen, Breda Mary
 PATENT ASSIGNEE(S): Ethicon, Inc., USA
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2005049101	A1	20050602	WO 2004-GB4838	20041117
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
GB 2408206	A	20050525	GB 2003-26844	20031118
GB 2408206	B	20071128		
EP 1684813	A1	20060802	EP 2004-798557	20041117
R:	DE, ES, FR, GB, IT			
JP 2007511313	T	20070510	JP 2006-540582	20041117
US 2007100269	A1	20070503	US 2006-579850	20060517
PRIORITY APPLN. INFO.:			GB 2003-26844	A 20031118
			WO 2004-GB4838	W 20041117

AB A wound dressing material comprising a polymeric substrate, a silver salt, and a dyestuff to photostabilize the silver salt. The substrate may comprise collagen and/or oxidized regenerated cellulose complexed to Ag+, and the dyestuff may be an aniline or acridine dye. Also provided are methods of making such materials, and wound dressings comprising such materials. An antioxidant and antimicrobial wound dressing material based on a collagen/ORC freeze-dried sponge material is prepared. Methylene blue, an acidic dye, was incorporated by dissolving an appropriate amount of the dye in 0.05M acetic acid and adding to the collagen paste with the milled ORC powder to obtain a slurry. Silver is incorporated by dissolving silver acetate in 0.05M acetic acid and adding the solution to the slurry to achieve a final solids concentration in the slurry of 1%.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:445187 CAPLUS

DOCUMENT NUMBER: 142:487681

TITLE: Wound dressing for the controlled release of therapeutic agents comprising also an inhibitor of a protease enzyme and a linker group cleavable by such an enzyme

INVENTOR(S): Cullen, Breda Mary; Gregory, Sara Jayne

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: Brit. UK Pat. Appl., 23 pp.
CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
GB 2408207	A	20050525	GB 2003-27326	20031124
AU 2004292396	A1	20050609	AU 2004-292396	20041118
CA 2542259	A1	20050609	CA 2004-2542259	20041118
WO 2005051441	A1	20050609	WO 2004-GB4874	20041118

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1687039 A1 20060809 EP 2004-798588 20041118

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, IS

US 2007148214 A1 20070628 US 2006-579897 20060519

PRIORITY APPLN. INFO.: GB 2003-27326 A 20031124

WO 2004-GB4874 W 20041118

AB A wound dressing material for controlled activation of a wound healing therapeutic compound in the presence of a protease enzyme in a wound fluid comprises a medically acceptable polymer; a wound healing therapeutic agent; an inhibitor of the protease enzyme; and a linker group which is cleavable by the protease enzyme, wherein the activities of both the wound healing therapeutic agent and the inhibitor are increased by contacting the wound dressing material with a wound fluid containing the protease enzyme. The polymer may be cross-linked to the linker group; the wound healing therapeutic agent and/or the inhibitor may be conjugated to the medically acceptable polymer by the linker group; or the wound healing therapeutic agent may be conjugated to the inhibitor by the linker group. The therapeutic agent may be a reactive oxygen scavenger (i.e. antioxidant), an antimicrobial agent (e.g. antibiotic), a pain relieving agent (e.g. anti-inflammatory), an antiseptic, an analgesic, a local anesthetic, or a growth factor. The enzyme inhibitor may be selected from the group consisting of tissue inhibitor of metalloproteinase, 4-(2-aminoethyl)benzenesulfonyl fluoride, antithrombin, (p-amidinophenyl)methanesulfonyl fluoride, aprotinin, diisopropylfluorophosphate, Ph Me sulfonyl fluoride, antipain, chymostatin, leupeptin, tosyl-lysine chloromethylketone, tosyl-Ph chloromethylketone, L-trans-epoxysuccinylleucylamido (4-guanidino) butane, E-64, amastatin, bestatin, diprotin, ethylenediamine tetra-acetic acid, pepstatin and mixts. thereof. Preferably, the enzyme may be a matrix metalloproteinase, the therapeutic agent may be a reactive oxygen scavenger, and the inhibitor may be a tissue inhibitor or metalloproteinase.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:1154593 CAPLUS

DOCUMENT NUMBER: 142:80021

TITLE: Antioxidant wound dressing materials

INVENTOR(S): Cullen, Breda Mary; Addison, Deborah; Greenhalgh, David

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 3

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
WO 2004112850	A1	20041229	WO 2004-GB2636	20040621
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2402882	A	20041222	GB 2003-14454	20030620
GB 2402882	B	20070328		
GB 2408206	A	20050525	GB 2003-26844	20031118
GB 2408206	B	20071128		
AU 2004248971	A1	20041229	AU 2004-248971	20040621
CA 2529413	A1	20041229	CA 2004-2529413	20040621
EP 1641499	A1	20060405	EP 2004-742989	20040621
R: DE, ES, FR, GB, IT, NL				
CN 1838970	A	20060927	CN 2004-80023815	20040621
JP 2007515979	T	20070621	JP 2006-516448	20040621
US 2006159732	A1	20060720	US 2005-560544	20051214
IN 2006KN00003	A	20070622	IN 2006-KN3	20060102
PRIORITY APPLN. INFO.:			GB 2003-14454	A 20030620
			US 2003-491991P	P 20030804
			GB 2003-26844	A 20031118
			WO 2004-GB2636	W 20040621
AB			A wound dressing material comprising a solid bioabsorbable substrate dyed with an antioxidant dyestuff. The substrate may comprise collagen, chitosan or oxidized regenerated cellulose, and the dyestuff may for example be an aniline or acridine dye. The material preferably also comprises a silver salt, whereby the dyestuff stabilizes the silver salt. Also provided are methods of making such materials, and wound dressings comprising such materials. The dye materials showed higher activity in the DPPH test.	
REFERENCE COUNT:	6	THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		
L4	ANSWER 14 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN			
ACCESSION NUMBER:	2004:1121859 CAPLUS			
DOCUMENT NUMBER:	142:62794			
TITLE:	Bioabsorbable wound dressing containing an antioxidant dye			
INVENTOR(S):	Cullen, Breda Mary; Addison, Deborah; Greenhalgh, David			
PATENT ASSIGNEE(S):	Johnson & Johnson Medical Limited, UK			
SOURCE:	Brit. UK Pat. Appl., 19 pp. CODEN: BAXXDU			
DOCUMENT TYPE:	Patent			
LANGUAGE:	English			
FAMILY ACC. NUM. COUNT:	3			
PATENT INFORMATION:				

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----
GB 2402882	A	20041222	GB 2003-14454	20030620
GB 2402882	B	20070328		

AU 2004248971 A1 20041229 AU 2004-248971 20040621
CA 2529413 A1 20041229 CA 2004-2529413 20040621
WO 2004112850 A1 20041229 WO 2004-GB2636 20040621

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1641499 A1 20060405 EP 2004-742989 20040621

R: DE, ES, FR, GB, IT, NL

CN 1838970 A 20060927 CN 2004-80023815 20040621

JP 2007515979 T 20070621 JP 2006-516448 20040621

US 2006159732 A1 20060720 US 2005-560544 20051214

IN 2006KN00003 A 20070622 IN 2006-KN3 20060102

PRIORITY APPLN. INFO.:

GB 2003-14454 A 20030620

US 2003-491991P P 20030804

GB 2003-26844 A 20031118

WO 2004-GB2636 W 20040621

AB A wound dressing material comprises a solid bioabsorbable substrate dyed with an antioxidant dyestuff. The substrate may comprise collagen, oxidized regenerated cellulose, alginates, chitosans, galactomannans, glycosaminoglycans and mixts. thereof. The dyestuff may be selected from a group consisting of aniline dyes, acridine dyes, thionine dyes, bis-naphthalene dyes, thiazine dyes, azo dyes, anthraquinones and mixts. thereof. The dressing may be for the treatment of ulcers, especially, venous ulcer, or diabetic ulcer. The material for the wound dressing may have a free radical activity in the diphenylpicrylhydrazyl test for antioxidant activity of at least 15%. Also provided is a method of making such materials and wound dressing comprising such materials.

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:965119 CAPLUS

DOCUMENT NUMBER: 141:401017

TITLE: Pain-sensitive therapeutic wound dressings

INVENTOR(S): Trotter, Patrick John; Cullen, Breda Mary

PATENT ASSIGNEE(S): Johnson & Johnson Medical

Limited, UK

SOURCE: PCT Int. Appl., 21 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004096302	A1	20041111	WO 2004-GB1774	20040427
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			

RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

GB 2401041 A 20041103 GB 2003-9645 20030428

GB 2401041 B 20070808

EP 1620138 A1 20060201 EP 2004-729670 20040427

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 2006286155 A1 20061221 US 2005-554375 20051025

PRIORITY APPLN. INFO.: GB 2003-9645 A 20030428

US 2003-526973P P 20031203

WO 2004-GB1774 W 20040427

AB The invention provides a wound dressing comprising a therapeutic agent and a matrix comprising polymers crosslinked by oligopeptide sequences which are cleavable by a kallikrein associated with a wound fluid such that the rate of release of the therapeutic agent increases in the presence of elevated kallikrein levels.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 16 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:923217 CAPLUS

DOCUMENT NUMBER: 141:400989

TITLE: Pain-sensitive therapeutic wound dressings containing matrix of polymers crosslinked with oligopeptides

INVENTOR(S): Trotter, Patrick John; Cullen, Breda Mary

PATENT ASSIGNEE(S): Johnson & Johnson Medical

Limited, UK

SOURCE: Brit. UK Pat. Appl., 19 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
GB 2401041	A	20041103	GB 2003-9645	20030428
GB 2401041	B	20070808		
WO 2004096302	A1	20041111	WO 2004-GB1774	20040427

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
SN, TD, TG

EP 1620138 A1 20060201 EP 2004-729670 20040427

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK

US 2006286155 A1 20061221 US 2005-554375 20051025

PRIORITY APPLN. INFO.: GB 2003-9645 A 20030428

US 2003-526973P P 20031203

WO 2004-GB1774 W 20040427

AB The invention provides a wound dressing comprising a therapeutic agent and

a matrix comprising polymers joined by crosslinkages which crosslinkages comprise oligopeptidic sequences which are cleavable by a kallikrein associated with wound fluid such that the rate of release of the therapeutic agent increases in the presence of elevated kallikrein levels. For example, the polymer is a homopolymer of N-2-hydroxypropyl methacrylamide, the oligopeptide comprises of sequence of Phe-Arg-Ser-Ser-Arg-Gln, and the therapeutic agent can be antimicrobials, analgesics, anesthetics and kallikrein inhibitor.

REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:824125 CAPLUS

DOCUMENT NUMBER: 141:330796

TITLE: Prediction and detection of wound infection by measuring inflammatory cytokine levels in wound fluid

INVENTOR(S): Cullen, Breda Mary

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: PCT Int. Appl., 16 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004086043	A1	20041007	WO 2004-GB1294	20040325
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2399881	A	20040929	GB 2003-6979	20030326
GB 2399881	B	20070425		

PRIORITY APPLN. INFO.: GB 2003-6979 A 20030326

US 2003-492750P P 20030806

AB A method of predicting or diagnosing clin. infection of a wound comprising measuring the concentration of a marker associated with an inflammatory response in wound fluid, wherein the marker is a proinflammatory cytokine, such as TNF- α . Also provided is a use of a wound dressing or biosensor comprising components of an assay system for measuring the concentration of a marker associated with an inflammatory response, wherein the marker is a proinflammatory cytokine, such as TNF- α , for the manufacture of a medicament for predicting the likelihood of clin. infection of the wound, or for diagnosing clin. infection of a wound. The examples (increase in tumor necrosis factor formation observed in the wound fluid collected from 2 patients with diabetic foot ulcers; the effect of bacterial lipopolysaccharide on tumor necrosis factor formation by human neutrophils isolated from whole blood; and the tumor necrosis factor formation by a monocyte/macrophage cell line cultured in vitro and stimulated with lipopolysaccharide) illustrate that measurement of tumor necrosis factor is highly promising for early-stage prognostic/diagnostic detection of

wound infection, even before any apparent clin. signs.
REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:794598 CAPLUS
DOCUMENT NUMBER: 141:301543
TITLE: Diagnosing wound infections
INVENTOR(S): Cullen, Breda Mary
PATENT ASSIGNEE(S): Johnson & Johnson Medical
Limited, UK
SOURCE: Brit. UK Pat. Appl., 15 pp.
CODEN: BAXXDU
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
GB 2399881	A	20040929	GB 2003-6979	20030326
GB 2399881	B	20070425		
WO 2004086043	A1	20041007	WO 2004-GB1294	20040325
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: GB 2003-6979 A 20030326
US 2003-492750P P 20030806

AB A method of predicting or diagnosing clin. infection of a wound comprises
measuring the concentration of a marker associated with an inflammatory
response in
wound fluid, where the marker is a proinflammatory cytokine, e.g.
TNF- α . Also claimed is use of a wound dressing or biosensor
comprising components of an assay system for measuring the concentration of a
marker associated with an inflammatory response, wherein the marker is a
proinflammatory cytokine, for the manufacture of a medicament for predicting
the likelihood of clin. infection of the wound or, for diagnosing clin.
infection of a wound Immuno, colorimetric, fluorimetric etc. methods may
be used for detecting the marker concentration Wound fluid was collected from
two patients having diabetic foot ulcers of at least 30 days duration and
total protein and levels of TNF- α was measured. The non-infected
wound fluid contained 22.2 pg/mL, and when adjusted for total protein 6.36
pg/mL/mg of TNF- α . The infected wound fluid contained 135.6 pg/mL,
and when adjusted for protein 64.2 pg/mL/mg of TNF- α .

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:290453 CAPLUS
DOCUMENT NUMBER: 140:309491
TITLE: Wound treatment device
INVENTOR(S): Addison, Deborah; Essler, Alicia Joanna; Cullen,
Breda Mary; Silcock, Derek Walter

PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: PCT Int. Appl., 19 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028423	A1	20040408	WO 2003-GB4118	20030925
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
GB 2393655	A	20040407	GB 2002-22527	20020927
GB 2393655	B	20050824		
AU 2003267624	A1	20040419	AU 2003-267624	20030925
EP 1542632	A1	20050622	EP 2003-748316	20030925
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
US 2006111657	A1	20060525	US 2005-528742	20051006
PRIORITY APPLN. INFO.:			GB 2002-22527	A 20020927
			US 2003-486445P	P 20030714
			WO 2003-GB4118	W 20030925

AB A wound treatment device comprises a water-impermeable envelope having at least one aperture, wherein the envelope contains a therapeutic substance, and wherein the at least one aperture in the envelope is blocked by a material that breaks down in the presence of one or more active components of wound fluid thereby permitting the therapeutic substance to contact the wound fluid. Preferably, the aperture is blocked by a material that is a substrate for an enzyme present in wound fluid, such as a protease. A device was prepared having an aperture of a sheet occluded by a thin film of Type I collagen.

L4 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:282762 CAPLUS
 DOCUMENT NUMBER: 140:309374
 TITLE: Wound treatment device comprising therapeutic agents and biodegradable polymers
 INVENTOR(S): Addison, Deborah; Essler, Alicia; Cullen, Breda Mary
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: Brit. UK Pat. Appl., 18 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2393655	A	20040407	GB 2002-22527	20020927
GB 2393655	B	20050824		

WO 2004028423 A1 20040408 WO 2003-GB4118 20030925
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
AU 2003267624 A1 20040419 AU 2003-267624 20030925
EP 1542632 A1 20050622 EP 2003-748316 20030925
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
US 2006111657 A1 20060525 US 2005-528742 20051006
PRIORITY APPLN. INFO.: GB 2002-22527 A 20020927
US 2003-486445P P 20030714
WO 2003-GB4118 W 20030925

AB A wound treatment device comprises a water-impermeable envelope having at least one aperture, wherein the envelope contains a therapeutic substance, and wherein the at least one aperture in the envelope is blocked by a material that breaks down in the presence of one or more components of wound fluid thereby permitting the therapeutic substance to contact the wound fluid. Preferably, the aperture is blocked by a material that is a substrate for an enzyme present in wound fluid, such as a protease. The degradable material may comprise elastin, fibronectin, collagen, crosslinked gelatin, fibrinogen, casein, hyaluronates, plasminogen fibrin, chitin, chitosan, oxidized cellulose or polylactide/polyglycolide copolymers.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2004:240130 CAPLUS

DOCUMENT NUMBER: 140:276154

TITLE: Wound dressing compositions comprising chitosan and oxidized regenerated cellulose and use for chronic wound treatment

INVENTOR(S): Cullen, Breda Mary; Silcock, Derek Walter

PATENT ASSIGNEE(S): Johnson & Johnson Medical

Limited, UK

SOURCE: Brit. UK Pat. Appl., 28 pp.

CODEN: BAXXDU

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2393120	A	20040324	GB 2002-21688	20020918
CA 2499498	A1	20040401	CA 2003-2499498	20030917
WO 2004026200	A2	20040401	WO 2003-GB4019	20030917
WO 2004026200	A3	20040902		
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,				
GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,				
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ,				
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,				
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES,
 FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
 AU 2003264890 A1 20040408 AU 2003-264890 20030917
 EP 1539258 A2 20050615 EP 2003-797383 20030917
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK
 JP 2006514843 T 20060518 JP 2004-537288 20030917
 US 2006172000 A1 20060803 US 2005-528262 20051118
 PRIORITY APPLN. INFO.: GB 2002-21688 A 20020918
 WO 2003-GB4019 W 20030917

AB The present invention relates to a wound dressing composition comprising a
 chitosan and an oxidized regenerated cellulose and its use for wound
 treatment. For example, the composition may be in the form of a sponge formed
 by freeze drying an aqueous dispersion of chitosan and oxidized regenerated
 cellulose (ORC). The composition is especially suitable for the treatment of
 chronic wounds. A method of separating cell growth factors from a biol. sample or
 organism using the composition is also outlined.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2004:213319 CAPLUS
 DOCUMENT NUMBER: 140:241066
 TITLE: Complex of an anionic polysaccharide with silver,
 manufacture of complex, and use
 INVENTOR(S): Cullen, Breda Mary; Addison, Deborah; Greenhalgh,
 David; Essler, Alicia
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: Brit. UK Pat. Appl., 26 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2392913	A	20040317	GB 2002-21062	20020911
GB 2392913	B	20070404		
CA 2495541	A1	20040325	CA 2003-2495541	20030910
WO 2004024197	A1	20040325	WO 2003-GB3898	20030910
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003263344	A1	20040430	AU 2003-263344	20030910
EP 1536845	A1	20050608	EP 2003-795068	20030910
EP 1536845	B1	20070425		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005537882	T	20051215	JP 2004-535645	20030910

AT 360444	T	20070515	AT 2003-795068	20030910
ES 2286497	T3	20071201	ES 2003-3795068	20030910
US 2006149182	A1	20060706	US 2005-527421	20051118
PRIORITY APPLN. INFO.:			US 2002-414381P	P 20020930
			GB 2002-21062	A 20020911
			WO 2003-GB3898	W 20030910

AB The complex is preferably a salt formed between the polysaccharide and Ag and the anionic polysaccharide is preferably a polycarboxylate. The anionic polysaccharide may be selected from alginates, hyaluronates, pectins, carrageenans, xanthan gums, sulfated dextrans, cellulose derivs., oxidized celluloses e.g. oxidized regenerated cellulose fiber (ORC), and mixts. A wound dressing, such as a sponge sheet, a woven or nonwoven fabric, or a gel sheet, comprises a complex of an anionic polysaccharide with Ag for treating ulcers. The wound dressing may further comprise collagen and preferably also comprises oxidized regenerated cellulose. Significant bactericidal effects were observed against Staphylococcus aureus for the materials containing $\geq 1\%$ silver-ORC complex.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
 ACCESSION NUMBER: 2003:454018 CAPLUS
 DOCUMENT NUMBER: 139:26648
 TITLE: Controlled release therapeutic wound dressings
 INVENTOR(S): Cullen, Breda Mary; Silcock, Derek; Warrick, Jonathan
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: Brit. UK Pat. Appl., 18 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2382775	A	20030611	GB 2001-29292	20011206
GB 2382775	B	20050525		
WO 2003047643	A1	20030612	WO 2002-GB5522	20021206
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002347354	A1	20030617	AU 2002-347354	20021206
EP 1463539	A1	20041006	EP 2002-783289	20021206
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
JP 2005511147	T	20050428	JP 2003-548897	20021206
US 2005159695	A1	20050721	US 2005-497442	20050303
PRIORITY APPLN. INFO.:			GB 2001-29292	A 20011206
			WO 2002-GB5522	W 20021206

AB A wound dressing comprising: a therapeutic agent selected from the group consisting of antimicrobial substances, pain relieving substances, protease inhibitors, and mixts. thereof; and a barrier layer for initially separating the therapeutic agent from a wound fluid in use, wherein the barrier

layer comprises a substrate for an enzyme selected from the group consisting of proteases, kallikrein and tissue-plasminogen activator. Preferably the substrate comprises a substrate for elastase or a collagenase. The barrier layer breaks down in infected or chronic wounds, thereby releasing the therapeutic substance selectively into such wounds.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 24 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:377083 CAPLUS
DOCUMENT NUMBER: 138:365158
TITLE: Wound monitoring
INVENTOR(S): Cullen, Breda Mary
PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK
SOURCE: PCT Int. Appl., 12 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040406	A2	20030515	WO 2002-GB5023	20021105
WO 2003040406	A3	20031016		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2002341191	A1	20030519	AU 2002-341191	20021105
EP 1453970	A2	20040908	EP 2002-774985	20021105
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
US 2005079542	A1	20050414	US 2004-494507	20040720
PRIORITY APPLN. INFO.:			GB 2001-26534	A 20011105
			WO 2002-GB5023	W 20021105

AB A method of predicting or diagnosing clin. infection of a wound comprising measuring the concentration of a marker associated with an inflammatory response in wound fluid, wherein the marker is a fibronectin fragment, a neutrophil protease or a macrophage protease. Also provided is a use of a wound dressing or biosensor comprising components of an assay system for measuring the concentration of a marker associated with an inflammatory response, wherein the marker is a fibronectin fragment, a neutrophil protease or a macrophage protease, for use in the manufacture of a medicament for predicting the likelihood of clin. infection of the wound or for diagnosing clin. infection of a wound.

L4 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:77703 CAPLUS
DOCUMENT NUMBER: 138:126994
TITLE: Apertured-sheet material containing water-swellaable hydrogel for would dressings

INVENTOR(S): Cullen, Breda Mary; Kirkwood, Andrew James
 PATENT ASSIGNEE(S): Johnson & Johnson Medical
 Limited, UK
 SOURCE: Brit. UK Pat. Appl., 18 pp.
 CODEN: BAXXDU
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
GB 2377939	A	20030129	GB 2001-18250	20010726
GB 2377939	B	20050420		
WO 2003011352	A1	20030213	WO 2002-GB3406	20020725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002317395	A1	20030217	AU 2002-317395	20020725
EP 1409030	A1	20040421	EP 2002-745682	20020725
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
TW 589337	B	20040601	TW 2002-91116522	20020725
JP 2004536670	T	20041209	JP 2003-516582	20020725
PRIORITY APPLN. INFO.:			GB 2001-18250	A 20010726
			WO 2002-GB3406	W 20020725

AB A self-supporting apertured sheet consists essentially of a water-swellaable hydrogel composition, wherein the area of the apertures is up to about 50% of the area of the sheet before swelling. A method of making such sheets comprises the steps of: providing an apertured substrate sheet (e.g., polyethylene film); coating an aqueous hydrogel precursor onto the apertured substrate (e.g., gelatin); curing the aqueous hydrogel precursor on the substrate to form an apertured hydrogel layer on the substrate sheet; and separating the apertured hydrogel layer from the substrate sheet.

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 26 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:785992 CAPLUS

DOCUMENT NUMBER: 139:73980

TITLE: The role of oxidized regenerated cellulose/collagen in wound repair: effects in vitro on fibroblast biology and in vivo in a model of compromised healing

AUTHOR(S): Hart, Jeffrey; Silcock, Derek; Gunnigle, Stephen; Cullen, Breda; Light, Nicholas D.; Watt, Paul W.

CORPORATE SOURCE: St. James's University Hospital, Molecular Medicine Unit, Wound Repair Programme, University of Leeds, Leeds, LS9 7TF, UK

SOURCE: International Journal of Biochemistry & Cell Biology

(2002), 34(12), 1557-1570

CODEN: IJBBFU; ISSN: 1357-2725

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Irresp. of underlying chronic wound pathol., delayed wound healing is normally characterized by impaired new tissue formation at the site of injury. It is thought that this impairment reflects both a reduced capacity to synthesize new tissue and the antagonistic activities of high levels of proteinases within the chronic wound environment. Historically, wound dressings have largely been passive devices that offer the wound interim barrier function and establish a moist healing environment. A new generation of devices, designed to interact with the wound and promote new tissue formation, is currently being developed and tested. This study considers one such device, oxidized regenerated cellulose (ORC) /collagen, in terms of its ability to promote fibroblast migration and proliferation in vitro and to accelerate wound repair in the diabetic mouse, a model of delayed wound healing. ORC/collagen was found to promote both human dermal fibroblasts proliferation and cell migration. In vivo studies considered the closure and histol. characteristics of diabetic wounds treated with ORC/collagen compared to those of wounds given standard treatment on both diabetic and non-diabetic mice. ORC/collagen was found to significantly accelerate diabetic wound closure and result in a measurable improvement in the histol. appearance of wound tissues. As the diabetic mouse is a recognized model of impaired healing, which may share some characteristics of human chronic wounds, the results of this in vivo study, taken together with those relating the pos. effects of ORC/collagen in vitro, may predict the beneficial use of this device in the clin. setting.

REFERENCE COUNT: 67 THERE ARE 67 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 27 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:785991 CAPLUS

DOCUMENT NUMBER: 139:73979

TITLE: The role of oxidized regenerated cellulose/collagen in chronic wound repair and its potential mechanism of action

AUTHOR(S): Cullen, Breda; Watt, Paul W.; Lundqvist, Charlotte; Silcock, Derek; Schmidt, Richard J.; Bogan, Declan; Light, Nicholas D.

CORPORATE SOURCE: Johnson & Johnson Wound

Management, R&D Department, Division of ETHICON, Gargrave, BD23 3RX, UK

SOURCE: International Journal of Biochemistry

& Cell Biology

(2002), 34(12), 1544-1556

CODEN: IJBBFU; ISSN: 1357-2725

PUBLISHER: Elsevier Science Ltd.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Normal wound healing is a carefully controlled balance of destructive processes necessary to remove damaged tissue and repair processes which lead to new tissue formation. Proteases and growth factors play a pivotal role in regulating this balance, and if disrupted in favor of degradation then delayed healing ensues; a trait of chronic wounds. While there are many types of chronic wounds, biochem. they are thought to be similar in that they are characterized by a prolonged inflammatory phase, which results in elevated levels of proteases and diminished growth factor activity. This increase in proteolytic activity and subsequent degradation of growth factors is thought to contribute to the net tissue loss associated with these chronic wounds. In this study, we describe a new wound treatment, comprising oxidized regenerated cellulose and collagen (ORC/collagen), which can redress this imbalance and modify the chronic wound environment. We demonstrate that ORC/collagen can inactivate potentially harmful factors

such as proteases, oxygen free radicals and excess metal ions present in chronic wound fluid, while simultaneously protecting pos. factors such as growth factors and delivering them back to the wound. These characteristics suggest a beneficial role for this material in helping to re-balance the chronic wound environment and therefore promote healing.

REFERENCE COUNT: 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 28 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2002:777749 CAPLUS
DOCUMENT NUMBER: 137:284370
TITLE: Peptides for the treatment of wound contracture
INVENTOR(S): Cullen, Breda Mary; Silcock, Derek Walter
PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK
SOURCE: PCT Int. Appl., 14 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002078728	A2	20021010	WO 2002-GB1173	20020326
WO 2002078728	A3	20030417		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
GB 2373724	A	20021002	GB 2001-7761	20010328
GB 2373724	B	20050202		
AU 2002241098	A1	20021015	AU 2002-241098	20020326
EP 1372693	A2	20040102	EP 2002-706935	20020326
EP 1372693	B1	20060614		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2004523591	T	20040805	JP 2002-576993	20020326
AT 329609	T	20060715	AT 2002-706935	20020326
PRIORITY APPLN. INFO.:			GB 2001-7761	A 20010328
			WO 2002-GB1173	W 20020326

OTHER SOURCE(S): MARPAT 137:284370

AB The present invention provides the use of a peptide derivative having the sequence X-NH-Gly-Pro-Ala-Gly-CO-Y, wherein X is H or a pharmaceutically acceptable N-terminal group, and Y is OH or a pharmaceutically acceptable C-terminal group, for the preparation of a medicament for use in the treatment or prevention of wound contracture.

L4 ANSWER 29 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:265287 CAPLUS
DOCUMENT NUMBER: 134:271294
TITLE: Oxidized cellulose for the treatment of wound contracture
INVENTOR(S): Cullen, Breda Mary; Silcock, Derek Walter
PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001024841	A1	20010412	WO 2000-GB3744	20000929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2354708	A	20010404	GB 1999-23291	19991001
GB 2354708	B	20040602		
EP 1216066	A1	20020626	EP 2000-964446	20000929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2003511099	T	20030325	JP 2001-527840	20000929
PRIORITY APPLN. INFO.:			GB 1999-23291	A 19991001
			WO 2000-GB3744	W 20000929

AB The present invention provides the use of an oxidized cellulose for the preparation of a medicament for use in the treatment or prevention of wound contracture. Preferably, the oxidized cellulose is oxidized regenerated cellulose (ORC) or partially hydrolyzed ORC. Preparation of soluble hydrolyzed ORC from Surgicel was described. Formulation of an ointment containing 2% hydrolyzed ORC disclosed.

REFERENCE COUNT: 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 30 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:136964 CAPLUS

DOCUMENT NUMBER: 134:183548

TITLE: Easy to remove adhesive sheets for use in a wound dressing

INVENTOR(S): Patel, Dharmendra; Silcock, Derek; Cullen, Breda; Lowing, Paul Howard

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: PCT Int. Appl., 16 pp.
CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001012116	A1	20010222	WO 2000-GB3146	20000815
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
 DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
 CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 GB 2353219 A 20010221 GB 1999-19368 19990816
 GB 2353219 B 20040211
 EP 1204391 A1 20020515 EP 2000-953325 20000815
 EP 1204391 B1 20041013
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL
 JP 2003506197 T 20030218 JP 2001-516463 20000815
 PRIORITY APPLN. INFO.: GB 1999-19368 A 19990816
 WO 2000-GB3146 W 20000815

AB The invention provides an adhesive sheet for use in a wound dressing or the like, comprising: a backing layer; a layer of adhesive applied to a first side of the backing layer for adhering the adhesive sheet to a surface; and an elongate conduit for a fluid provided in or on said first side of the backing layer, wherein the conduit is provided with an inlet for introducing fluid into the conduit while the adhesive sheet is adhered to the surface to assist removal of the adhesive sheet from the surface. The invention also provides a similar adhesive sheet in which the elongate conduit is replaced by an elongate reservoir containing a liquid release agent, wherein the reservoir can be ruptured to release the liquid therefrom into the adhesive layer while the adhesive sheet is adhered to the surface to assist removal of the adhesive sheet from the surface. A bottom plans view of an island-type wound dressing incorporating an adhesive sheet according to the present invention is depicted (no data).

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:401694 CAPLUS

DOCUMENT NUMBER: 133:34483

TITLE: Sterile complex of therapeutic peptide bonded to a polysaccharide

INVENTOR(S): Cullen, Breda; Silcock, Derek; Van Leeuwen, Peter; Harvey, Wilson

PATENT ASSIGNEE(S): Johnson & Johnson Medical Limited, UK

SOURCE: PCT Int. Appl., 41 pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000033893	A1	20000615	WO 1999-GB4094	19991206
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
GB 2344519	A	20000614	GB 1998-26897	19981207
GB 2344519	B	20040519		
CA 2319327	A1	20000615	CA 1999-2319327	19991206
BR 9907679	A	20001024	BR 1999-7679	19991206
EP 1053029	A1	20001122	EP 1999-958396	19991206

EP 1053029	B1	20030910		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
SI 20306	A	20010228	SI 1999-20021	19991206
JP 2002531532	T	20020924	JP 2000-586383	19991206
AT 249249	T	20030915	AT 1999-958396	19991206
AU 771733	B2	20040401	AU 2000-15770	19991206
IN 2000KN00137	A	20050311	IN 2000-KN137	20000714
HK 1032362	A1	20040130	HK 2001-102883	20010423
PRIORITY APPLN. INFO.:			GB 1998-26897	A 19981207
			WO 1999-GB4094	W 19991206

AB The invention provides sterile compns. comprising a complex of a therapeutic peptide and a polysaccharide selected from the group consisting of cellulose derivs., chitin, chitosans, galactomannans, and mixts. thereof, wherein the complex has been sterilized with ionizing radiation. The presence of the polysaccharides surprisingly stabilizes therapeutic peptides against decomposition under ionizing conditions, especially under gamma-irradiation Processes for the preparation of the sterile compns. and processes for the preparation of sterile therapeutic peptides are also claimed. For example, a sterile pharmaceutical gel for topical administration to promote wound healing was formulated containing CM-cellulose 2.4, hydroxyethyl cellulose 0.3, NaCl 0.24, propylene glycol 20.2, collagen/oxidized regenerated cellulose/platelet-derived growth factor (1 weight%) 2.0, and water up to 100%, resp.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 32 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:180118 CAPLUS

DOCUMENT NUMBER: 126:259571

TITLE: The differential regulation and secretion of proteinases from fetal and neonatal fibroblasts by growth factors

AUTHOR(S): Cullen, Breda; Silcock, Derek; Brown, Laura J.; Gosiewska, Anna; Geesin, Jeffrey C.

CORPORATE SOURCE: Johnson and Johnson Wound Healing Technology Resource Center, Skillman, NJ, 08558-9418, USA

SOURCE: International Journal of Biochemistry & Cell Biology

(1997), 29(1), 241-250

CODEN: IJBBFU; ISSN: 1357-2725

PUBLISHER: Elsevier

DOCUMENT TYPE: Journal

LANGUAGE: English

AB One of the major differences between fetal and adult wound repair is the unique ability of fetal wounds to heal without scarring. Since scar formation is a function of extracellular matrix deposition, the regulation of this component is fundamental in tissue remodeling. In this study, the authors have characterized the differences in the secretion of matrix-degrading proteases, namely urokinase plasminogen activator and gelatinase A and B, from fetal and neonatal fibroblasts. In addition, the authors examined the modulation of these protease levels by growth factors known to be important in wound repair. The results indicate that the secretion of these proteases differ significantly between the two cell types. The levels of urokinase plasminogen activator and its inhibitor were notably higher in media conditioned by neonatal fibroblasts in comparison to fetal samples. In contrast, the basal level of gelatinase A was comparable in both cell types, while the level of gelatinase B was elevated in the fetal fibroblasts. Transforming growth factor- β 1

reduced the level of urokinase plasminogen activator and stimulated the secretion of plasminogen activator inhibitor-1 and progelatinase B in both neonatal and fetal fibroblasts. However, only progelatinase A and an activated form of gelatinase B were significantly elevated in fetal fibroblasts. In contrast, platelet-derived growth factor stimulated urokinase plasminogen activator, its inhibitor and both gelatinase A and B, an effect which was more apparent in fetal fibroblasts. This difference in protease regulation may be reflected in the differing rate and quality of tissue remodeling observed during adult vs. fetal wound repair.

REFERENCE COUNT: 57 THERE ARE 57 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:443136 CAPLUS

DOCUMENT NUMBER: 117:43136

TITLE: The synthesis, kinetic characterization and application of a novel biotinylated affinity label for cathepsin B

AUTHOR(S): Walker, Brian; Cullen, Breda M.; Kay, Gillian;

Halliday, Isla M.; McGinty, Ann; Nelson, John
CORPORATE SOURCE: Sch. Biol. Biochem., Queen's Univ. Belfast, Belfast, BT9 7BL, UK

SOURCE: Biochemical Journal (1992), 283(2), 449-53

CODEN: BIJOAK; ISSN: 0306-3275

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The synthesis, kinetic characterization, and application of a novel biotinylated and active-site-directed inactivator of cathepsin B are reported. Thus, the peptidyl diazomethane biotinyl-Phe-Ala-diazomethane has been synthesized by a combination of solid-phase and solution methodologies and has been shown to be a very efficient inactivator of bovine and human cathepsin B. The resp. apparent second order rate consts. ($k_{\text{Obs.}}/[I]$) for the inactivation of the human and bovine enzymes by this reagent, namely $\text{.apprx.}5.4 \times 10^4 \text{ M}^{-1}\text{min}^{-1}$ and $\text{.apprx.}7.8 \times 10^4 \text{ M}^{-1}\text{min}^{-1}$, compare very favorably with those values determined for the urethane-protected analog benzyloxycarbonyl-Phe-Ala-chloromethane first described by A. D. J. Green and E. Shaw (1981), thus demonstrating that the presence of the biotin moiety at the P3 position is compatible with inhibitor effectiveness. The utilization of this reagent for the detection of cathepsin B in electrophoretic gels, using Western blotting and in combination with a streptavidin/alkaline phosphatase detection system, is also demonstrated. Given that the peptidyl diazomethanes exhibit a pronounced reactivity towards cysteine proteinases, the present label may well constitute the archetypal example of a wide range of reagents for the selective labeling of this class of proteinase, even in a complex biol. milieu containing addnl. classes of proteinases.

L4 ANSWER 34 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1992:422207 CAPLUS

DOCUMENT NUMBER: 117:22207

TITLE: The application of a novel biotinylated affinity label for the detection of a cathepsin B-like precursor produced by breast-tumor cells in culture

AUTHOR(S): Cullen, Breda M.; Halliday, Isla M.; Kay, Gillian;

Nelson, John; Walker, Brian
CORPORATE SOURCE: Sch. Biol. Biochem., Queen's Univ., Belfast, BT9 7BL, UK

SOURCE: Biochemical Journal (1992), 283(2), 461-5

CODEN: BIJOAK; ISSN: 0306-3275

DOCUMENT TYPE: Journal

LANGUAGE: English

AB In this report it is demonstrated how the recently developed biotinylated affinity label biotinyl-Phe-Ala-diazomethane (Bio-Phe-Ala-CHN2) can be used for the detection of a precursor form of a cathepsin B-like enzyme produced by breast-tumor cells in culture. Thus the cell lines MDA-MB-436, ZR-75-1 and T47-D produce a soluble protein that can be allowed to react with the biotinylated affinity label to yield an SDS-resistant complex; this can be revealed with a streptavidin/alkaline phosphatase label after PAGE and Western blotting. This protein (mol. mass 47 kDa) can also be detected by immunoblotting using sheep anti-(cathepsin B) antibodies in conjunction with a donkey anti-sheep IgG label. None of the cell lines studied produced any mature cathepsin B-like activity, as gauged by the lack of turnover of the fluorogenic substrate benzyloxycarbonyl-Arg-Arg-4-methylcoumarin-7-ylamide (Cbz-Arg-Arg-NH-Mec). However, treatment of medium samples with pepsin resulted in the generation of such activity. When the pepsin-catalyzed activation step was analyzed by SDS/PAGE, the protein of 47 kDa was completely converted into two species of very similar mol. masses of 30.5 kDa and 29 kDa. Both these proteins can incorporate the biotinylated probe and, in common with the 47 kD species, they can be detected with the streptavidin/alkaline phosphatase label and immunoblotting. It is proposed that the 47 kD form is the pepsin-activable proform of these lower-mol.-mass species. The release of the proform from the estrogen-receptor (ER)-pos. breast-tumor cell lines ZR-75-1 and T47-D is stimulated 5-10 fold when these cells are grown in medium containing epidermal growth factor (EGF) at a concentration of 10 ng/mL. In contrast, there is no modulation in the amount of proform released by the ER-neg. cell line MDA-MB-436, over a range of EGF concentration from 0 to 100 ng/mL.

L4 ANSWER 35 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:419964 CAPLUS

DOCUMENT NUMBER: 113:19964

TITLE: Synthesis and activity of a novel, irreversible inhibitor of cathepsin B

AUTHOR(S): Cullen, Breda M.; McGinty, Ann; Walker, Brian; Nelson, John; Halliday, Isla; Bailie, Janice R.; Kay, Gillian

CORPORATE SOURCE: Med. Biol. Cent., Queen's Univ. Belfast, Belfast, BT9 7BL, UK

SOURCE: Biochemical Society Transactions (1990), 18(2), 315-16
CODEN: BCSTB5; ISSN: 0300-5127

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The peptidyl inhibitor, biotin-Phe-Ala-diazomethylketone, was synthesized and tested against bovine cathepsin B. It was shown that this inhibitor is an active site-directed, irreversible inhibitor which had been successfully combined with a receptor group which lends itself to visualization.

L4 ANSWER 36 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:231697 CAPLUS

DOCUMENT NUMBER: 112:231697

TITLE: Facile solubilization of tumor-associated cathepsin B by acid treatment

AUTHOR(S): Cullen, Breda M.; Nelson, John; Walker, Brian; McGivern, Margaret; Kay, Gillian

CORPORATE SOURCE: Med. Biol. Cent., Queen's Univ. Belfast, Belfast, BT9 7BL, UK

SOURCE: Biochemical Society Transactions (1990), 18(2), 317
CODEN: BCSTB5; ISSN: 0300-5127

DOCUMENT TYPE: Journal
LANGUAGE: English

AB The cell surface expression of a cathepsin B-like enzyme, found in association with the plasma membrane of human breast tumor cells (MDA.MB.436), was investigated. The cathepsin-like enzyme was fully dissociated by brief acid treatment. Thus, the enzyme, although not dissociated by washing the cells with a physiol. salt solution, is fully removed by brief acidification. This suggests that cathepsin B-like activity is not adsorbed non-specifically to the cell surface of the tumor cell, but is a peripherally bound membrane protein.1.

=> expand oxidized adj cellulose

ENTER FIELD CODE (BI):help

If you wish to look at index terms from a specific field or fields other than the default, enter up to three field codes separated by commas. To see a list of field codes for the current file, enter "HELP SFIELDS" at an arrow prompt (=>). If you take the default, you will see terms from the fields listed in parentheses in the prompt.

ENTER FIELD CODE (BI):

ENTER FIELD CODE (BI):help sfields

If you wish to look at index terms from a specific field or fields other than the default, enter up to three field codes separated by commas. To see a list of field codes for the current file, enter "HELP SFIELDS" at an arrow prompt (=>). If you take the default, you will see terms from the fields listed in parentheses in the prompt.

ENTER FIELD CODE (BI):it

E1	1	OXIDIZEC/IT
E2	43626	OXIDIZED/IT
E3	0 -->	OXIDIZED ADJ CELLULOSE/IT
E4	2	OXIDIZEDGLUTATHIONE/IT
E5	2	OXIDIZEDLORES/IT
E6	2428	OXIDIZER/IT
E7	992	OXIDIZERS/IT
E8	81	OXIDIZES/IT
E9	1	OXIDIZIBILITY/IT
E10	1	OXIDIZIBLE/IT
E11	1	OXIDIZIED/IT
E12	1	OXIDIZIER/IT

=> e oxidized cellulose

E1	3	OXIDIZEC/BI
E2	260719	OXIDIZED/BI
E3	0 -->	OXIDIZED CELLULOSE/BI
E4	4	OXIDIZEDAND/BI
E5	1	OXIDIZEDCOTTONSEED/BI
E6	1	OXIDIZEDED/BI
E7	1	OXIDIZEDFLAVOR/BI
E8	2	OXIDIZEDGLUTATHIONE/BI
E9	2	OXIDIZEDLORES/BI
E10	1	OXIDIZEDLY/BI
E11	1	OXIDIZEDMORE/BI
E12	1	OXIDIZEDSOLID/BI

=> file reg

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	231.18	231.39
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION

CA SUBSCRIBER PRICE

-49.60

-49.60

FILE 'REGISTRY' ENTERED AT 16:46:03 ON 15 JAN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 JAN 2008 HIGHEST RN 960583-85-1
DICTIONARY FILE UPDATES: 14 JAN 2008 HIGHEST RN 960583-85-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 29, 2007

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=> e oxidized cellulose/cn

E1	1	OXIDIZED CARBON BLACK/CN
E2	1	OXIDIZED CARBON FIBERS/CN
E3	0 -->	OXIDIZED CELLULOSE/CN
E4	1	OXIDIZED CHARCOAL/CN
E5	1	OXIDIZED COA/CN
E6	1	OXIDIZED COA SODIUM SALT/CN
E7	1	OXIDIZED COD OIL/CN
E8	1	OXIDIZED COD-LIVER OIL/CN
E9	1	OXIDIZED COENZYME A/CN
E10	1	OXIDIZED COENZYME A HEXAPOTASSIUM SALT/CN
E11	1	OXIDIZED COENZYME A HEXASODIUM SALT/CN
E12	1	OXIDIZED CYCLO-(CYSTEINYL HISTIDYL)/CN

=> e oxidized adj cellulose

E1	1	OXIDISPIRO/BI
E2	1159	OXIDIZED/BI
E3	0 -->	OXIDIZED ADJ CELLULOSE/BI
E4	7	OXIDIZER/BI
E5	4	OXIDIZES/BI
E6	1094	OXIDIZING/BI
E7	6	OXIDN/BI
E8	154856	OXIDO/BI
E9	1	OXIDOADENOSIN/BI
E10	8	OXIDOADENYL/BI
E11	8	OXIDOADENYLYL/BI
E12	4	OXIDOAGAR/BI

=> e cellulose/cm

'CELLULOSE' IS NOT A VALID NUMERIC VALUE

Only valid numeric terms can be EXPANDED in numeric fields. Valid
numeric terms are zero and any term with an absolute value between 1
E-78 and 1 E74. Non-numeric characters are not permitted in the
EXPAND command for numeric fields. To see a list of numeric and text

fields in the current file, enter "HELP SFIELDS" at an arrow prompt (=>).

=> e cellulose/cn

E1	1	CELLULON/CN
E2	1	CELLULOPHAGA LYTICA/CN
E3	1 -->	CELLULOSE/CN
E4	1	CELLULOSE (1-HYDROXYETHYLIDENE)DIPHOSPHONATE/CN
E5	1	CELLULOSE (2-(4-PYRIDYL)ETHYL)PHOSPHONATE SODIUM SALT/CN
E6	1	CELLULOSE (2-DIETHYLBUTYLAMMONIUM)PROPIONATE BROMIDE/CN
E7	1	CELLULOSE (2-HYDROXYPROPOXY)CARBONYLMETHYL ETHER/CN
E8	1	CELLULOSE (3,3'-(PHENYLIMINO)BIS(2-HYDROXYTRIMETHYL)) ETHER/ CN
E9	1	CELLULOSE (3-CHLOROPHENYL)URETHANE/CN
E10	1	CELLULOSE (3-HYDROXY-4-(2-PYRIDYLAZO)PHENOXY)-S-TRIAZINYL ET HER/CN
E11	1	CELLULOSE (4-HYDROXYPHENYL)ACETATE/CN
E12	1	CELLULOSE (BACILLUS STRAIN KSM-64 PRECURSOR)/CN

=> expand cellulose

ENTER FIELD CODE (BI):cn

E1	1	CELLULON/CN
E2	1	CELLULOPHAGA LYTICA/CN
E3	1 -->	CELLULOSE/CN
E4	1	CELLULOSE (1-HYDROXYETHYLIDENE)DIPHOSPHONATE/CN
E5	1	CELLULOSE (2-(4-PYRIDYL)ETHYL)PHOSPHONATE SODIUM SALT/CN
E6	1	CELLULOSE (2-DIETHYLBUTYLAMMONIUM)PROPIONATE BROMIDE/CN
E7	1	CELLULOSE (2-HYDROXYPROPOXY)CARBONYLMETHYL ETHER/CN
E8	1	CELLULOSE (3,3'-(PHENYLIMINO)BIS(2-HYDROXYTRIMETHYL)) ETHER/ CN
E9	1	CELLULOSE (3-CHLOROPHENYL)URETHANE/CN
E10	1	CELLULOSE (3-HYDROXY-4-(2-PYRIDYLAZO)PHENOXY)-S-TRIAZINYL ET HER/CN
E11	1	CELLULOSE (4-HYDROXYPHENYL)ACETATE/CN
E12	1	CELLULOSE (BACILLUS STRAIN KSM-64 PRECURSOR)/CN

=> expand oxidizedcellulose

ENTER FIELD CODE (BI):bi

E1	1	OXIDISPIRO/BI
E2	1159	OXIDIZED/BI
E3	0 -->	OXIDIZEDCELLULOSE/BI
E4	7	OXIDIZER/BI
E5	4	OXIDIZES/BI
E6	1094	OXIDIZING/BI
E7	6	OXIDN/BI
E8	154856	OXIDO/BI
E9	1	OXIDOADENOSIN/BI
E10	8	OXIDOADENYL/BI
E11	8	OXIDOADENYLYL/BI
E12	4	OXIDOAGAR/BI

=> expand oxidized adj cellulose/bi

E1	1	OXIDISPIRO/BI
E2	1159	OXIDIZED/BI
E3	0 -->	OXIDIZED ADJ CELLULOSE/BI
E4	7	OXIDIZER/BI
E5	4	OXIDIZES/BI
E6	1094	OXIDIZING/BI
E7	6	OXIDN/BI
E8	154856	OXIDO/BI
E9	1	OXIDOADENOSIN/BI

E10	8	OXIDOADENYL/BI
E11	8	OXIDOADENYLYL/BI
E12	4	OXIDOAGAR/BI

=> expand oxidized and cellulose

ENTER FIELD CODE (BI):bi

E1	1	OXIDISPIRO/BI
E2	1159	OXIDIZED/BI
E3	0	--> OXIDIZED AND CELLULOSE/BI
E4	7	OXIDIZER/BI
E5	4	OXIDIZES/BI
E6	1094	OXIDIZING/BI
E7	6	OXIDN/BI
E8	154856	OXIDO/BI
E9	1	OXIDOADENOSIN/BI
E10	8	OXIDOADENYL/BI
E11	8	OXIDOADENYLYL/BI
E12	4	OXIDOAGAR/BI

=> expand cellulose/bi

E1	6	CELLULOSAE/BI
E2	3	CELLULOSATE/BI
E3	9074	--> CELLULOSE/BI
E4	1	CELLULOSEBEADS/BI
E5	2	CELLULOSECARBOXYL/BI
E6	2	CELLULOSECARBOXYLATE/BI
E7	1	CELLULOSEDI/BI
E8	1	CELLULOSEDICARBOXYL/BI
E9	1	CELLULOSEDICARBOXYLATE/BI
E10	2	CELLULOSEEN/BI
E11	1	CELLULOSEGLYC/BI
E12	1	CELLULOSEGLYCOL/BI

=> search e3

L8 9074 CELLULOSE/BI

=> s l8 and oxidized

1159 OXIDIZED

L9 0 L8 AND OXIDIZED